

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

For the quarterly period ended June 30, 2009

OR

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

For the transition period from _____ to _____

Commission file number 0-26301

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

52-1984749
(I.R.S. Employer
Identification No.)

1110 Spring Street, Silver Spring, MD
(Address of Principal Executive Offices)

20910
(Zip Code)

(301) 608-9292

(Registrant's Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer
Non-accelerated filer
(do not check if a smaller reporting company)

Accelerated filer
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the issuer's common stock, par value \$.01 per share, as of July 28, 2009 was 26,582,352.



INDE X

	<u>Page</u>	
Part I.	FINANCIAL INFORMATION (UNAUDITED)	
Item 1.	Consolidated Financial Statements	3
	Consolidated Balance Sheets	3
	Consolidated Statements of Operations	4
	Consolidated Statements of Cash Flows	5
	Notes to Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	32
Part II.	OTHER INFORMATION	
Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	33
Item 4.	Submission of Matters to a Vote of Security Holders	44
Item 6.	Exhibits	45
SIGNATURES		

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

	June 30, 2009 (Unaudited)	December 31, 2008 (As Adjusted)(1)
Assets		
Current assets:		
Cash and cash equivalents	\$ 133,524	\$ 129,452
Marketable investments	86,361	106,596
Accounts receivable, net of allowance of none at June 30, 2009 and December 31, 2008	34,368	28,311
Other receivable	3,030	2,289
Prepaid expenses	9,188	11,600
Inventories, net	16,504	14,372
Deferred tax assets	4,903	4,827
Total current assets	287,878	297,447
Marketable investments	130,792	100,270
Marketable investments and cash—restricted	46,155	45,755
Goodwill and other intangibles, net	7,762	7,838
Property, plant, and equipment, net	283,006	222,717
Deferred tax assets	174,427	178,842
Other assets (\$8,344 and \$7,685 at June 30, 2009 and December 31, 2008, respectively measured under the fair value option)	21,651	21,665
Total assets	<u>\$ 951,671</u>	<u>\$ 874,534</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 19,696	\$ 20,334
Accrued expenses	24,113	20,853
Other current liabilities	32,408	16,506
Total current liabilities	76,217	57,693
Convertible senior notes	212,846	205,691
Lease obligation	29,789	29,261
Other liabilities	16,957	15,673
Total liabilities	335,809	308,318
Commitments and contingencies:		
Common stock subject to repurchase	10,882	10,882
Stockholders' equity:		
Preferred stock, par value \$.01, 10,000,000 shares authorized, no shares issued	—	—
Series A junior participating preferred stock, par value \$.01, 100,000 authorized, no shares issued	—	—
Common stock, par value \$.01, 100,000,000 shares authorized, 27,807,145 and 27,662,151 shares issued at June 30, 2009, and December 31, 2008, respectively, and 26,576,350 and 26,431,356 outstanding at June 30, 2009, and December 31, 2008, respectively	278	276
Additional paid-in capital	757,896	722,293
Accumulated other comprehensive loss	(2,727)	(5,913)
Treasury stock at cost, 1,230,795 shares at June 30, 2009 and December 31, 2008	(67,395)	(67,395)
Accumulated deficit	(83,072)	(93,927)
Total stockholders' equity	604,980	555,334
Total liabilities and stockholders' equity	<u>\$ 951,671</u>	<u>\$ 874,534</u>

See accompanying notes to consolidated financial statements.

(1) Adjusted for the retrospective adoption of Financial Accounting Standards Board (FASB) Staff Position No. APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement)* (FSP APB 14-1). See Note 9 : *Debt — Adoption of FSP APB 14-1*.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
	As Adjusted (1) (Unaudited)		As Adjusted (1) (Unaudited)	
Revenues:				
Net product sales	\$ 81,009	\$ 65,497	\$ 157,867	\$ 124,650
Service sales	2,648	2,393	5,178	4,620
License fees	323	666	665	1,333
Total revenues	<u>83,980</u>	<u>68,556</u>	<u>163,710</u>	<u>130,603</u>
Operating expenses:				
Research and development	28,646	19,141	49,605	40,217
Selling, general and administrative	49,371	23,093	78,589	42,424
Cost of product sales	9,015	6,564	17,081	12,739
Cost of service sales	1,069	768	1,989	1,479
Total operating expenses	<u>88,101</u>	<u>49,566</u>	<u>147,264</u>	<u>96,859</u>
(Loss) income from operations	(4,121)	18,990	16,446	33,744
Other (expense) income:				
Interest income	1,335	2,804	3,056	6,412
Interest expense	(3,248)	(3,601)	(5,885)	(6,285)
Equity loss in affiliate	(38)	(43)	(57)	(156)
Other, net	529	817	894	525
Total other (expense) income, net	<u>(1,422)</u>	<u>(23)</u>	<u>(1,992)</u>	<u>496</u>
(Loss) income before income tax	(5,543)	18,967	14,454	34,240
Income tax benefit (expense)	3,199	(6,905)	(3,599)	(12,467)
Net (loss) income	<u>\$ (2,344)</u>	<u>\$ 12,062</u>	<u>\$ 10,855</u>	<u>\$ 21,773</u>
Net (loss) income per common share:				
Basic	<u>\$ (0.09)</u>	<u>\$ 0.53</u>	<u>\$ 0.41</u>	<u>\$ 0.97</u>
Diluted	<u>\$ (0.09)</u>	<u>\$ 0.50</u>	<u>\$ 0.40</u>	<u>\$ 0.90</u>
Weighted average number of common shares outstanding:				
Basic	<u>26,491</u>	<u>22,600</u>	<u>26,466</u>	<u>22,467</u>
Diluted	<u>26,491</u>	<u>24,328</u>	<u>27,343</u>	<u>24,120</u>

See accompanying notes to consolidated financial statements.

(1) Adjusted for the retrospective adoption of FSP APB 14-1. See Note 9 : *Debt — Adoption of FSP APB 14-1*.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	Six Months Ended June 30,	
	2009	2008
	(as adjusted)(1)	
	(Unaudited)	
Cash flows from operating activities:		
Net income	\$ 10,855	\$ 21,773
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	4,168	2,002
Provision for bad debt and inventory obsolescence	705	495
Deferred tax benefit	3,599	12,467
Share-based compensation	48,420	13,721
Amortization of debt discount and debt issue costs	7,722	7,209
Amortization of discount or premium on investments	680	(858)
Equity loss in affiliate and other	(2,998)	602
Excess tax benefits from share-based compensation	(1,592)	(9,720)
Changes in operating assets and liabilities:		
Accounts receivable	(5,943)	(4,625)
Inventories	(896)	(3,284)
Prepaid expenses	2,529	1,022
Other assets	(608)	(390)
Accounts payable	(10,201)	12,761
Accrued expenses	3,219	6,843
Other liabilities	(2,006)	4,489
Net cash provided by operating activities	<u>57,653</u>	<u>64,507</u>
Cash flows from investing activities:		
Purchases of property, plant and equipment	(49,837)	(46,903)
Purchases of held-to-maturity investments	(116,986)	(222,511)
Purchases of available-for-sale investments	—	(24,600)
Sales of available-for-sale investments	—	36,850
Sales of trading investments	50	—
Maturities of held-to-maturity investments	114,781	149,096
Restrictions on cash	(8,994)	2,042
Net cash used by investing activities	<u>(60,986)</u>	<u>(106,026)</u>
Cash flows from financing activities:		
Proceeds from the exercise of stock options	6,112	18,003
Excess tax benefits from share-based compensation	1,592	9,720
Principal payments on debt	(240)	(50)
Net cash provided by financing activities	<u>7,464</u>	<u>27,673</u>
Effect of exchange rate changes on cash and cash equivalents	(59)	(145)
Net increase (decrease) in cash and cash equivalents	4,072	(13,991)
Cash and cash equivalents, beginning of period	129,452	139,323
Cash and cash equivalents, end of period	<u>\$ 133,524</u>	<u>\$ 125,332</u>
Supplemental schedule of cash flow information:		
Cash paid for interest	<u>\$ 625</u>	<u>\$ 625</u>
Cash paid for income taxes	<u>\$ 2,919</u>	<u>\$ 684</u>

See accompanying notes to consolidated financial statements.

(1) Adjusted for the retrospective adoption of FSP APB 14-1. See Note 9 : *Debt — Adoption of FSP APB 14-1*.

UNITED THERAPEUTICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2009
(UNAUDITED)

1. Organization and Business Description

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. We were incorporated in 1996 under the laws of the State of Delaware and our wholly-owned subsidiaries include Lung Rx, Inc., Unither Pharmaceuticals, Inc., Unither Telmed, Ltd., Unither.com, Inc., United Therapeutics Europe, Ltd., Unither Therapeutik GmbH, Unither Pharma, Inc., Medicomp, Inc., Unither Neurosciences, Inc., LungRx Limited, Unither Biotech Inc., and Unither Virology, LLC. As used in these notes to the consolidated financial statements, unless the context requires otherwise, the terms “we,” “us,” “our,” and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.

Our lead product is Remodulin[®] (treprostinil sodium) Injection (Remodulin). Remodulin was first approved in 2002 by the United States Food and Drug Administration (FDA) for use as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension (PAH). Subsequently, the FDA expanded its approval of Remodulin for intravenous use and for the treatment of patients who require transition from Flolan[®]. Remodulin is also approved for use in countries outside of the United States, predominantly for subcutaneous administration.

We have generated pharmaceutical revenues from sales of Remodulin and license fees in the United States, Canada, the European Union (EU), South America and Asia. In addition, we have generated non-pharmaceutical revenues from telemedicine products and services in the United States.

2. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by United States generally accepted accounting principles (GAAP) for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes contained in our Annual Report on Form 10-K for the year ended December 31, 2008. The financial statements as of December 31, 2008, and for the three- and six-month periods ended June 30, 2008, presented in this Quarterly Report on Form 10-Q have been adjusted for the retrospective adoption of FSP APB 14-1 on January 1, 2009. See Note 9 to these consolidated financial statements for further discussion.

In our management’s opinion, the accompanying consolidated financial statements contain all adjustments, including normal recurring adjustments, necessary to present fairly our financial position as of June 30, 2009, results of operations for the three- and six-month periods ended June 30, 2009 and 2008, and cash flows for the six months ended June 30, 2009 and 2008. Interim results are not necessarily indicative of results for an entire year. We have evaluated subsequent events through July 31, 2009, which is the date our financial statements were issued. No material subsequent events have occurred during the period from June 30, 2009 to July 31, 2009, that would require recognition in these financial statements.

3. Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market (current replacement cost) and consist of the following, net of reserves (in thousands):

	June 30, 2009	December 31, 2008
Remodulin:		
Raw materials	\$ 3,047	\$ 3,387
Work-in-progress	9,374	6,558
Finished goods	3,714	4,085
Remodulin delivery pumps and medical supplies	194	194
Cardiac monitoring equipment components and supplies	175	148
Total inventories	<u>\$ 16,504</u>	<u>\$ 14,372</u>

4. Fair Value Measurements

FASB's Statement of Financial Accounting Standards (SFAS) No. 157, *Fair Value Measurements* (SFAS 157), defines fair value and establishes a fair value hierarchy based on the quality and reliability of the inputs or assumptions used in fair value measurements. Assets and liabilities that are within the scope of SFAS 157 are required to be classified and disclosed in one of the following categories based on the lowest level input that is significant to a fair value measurement:

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable.

Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data.

Financial assets and liabilities subject to fair value measurements are as follows (in thousands):

	As of June 30, 2009			
	Level 1	Level 2	Level 3	Balance
Assets				
Auction-rate securities(1)	\$ —	\$ —	\$ 28,000	\$ 28,000
Auction-rate securities put option(2)	—	—	8,344	8,344
Available-for-sale equity investment	142	—	—	142
Money market funds(3)	88,113	—	—	88,113
Federally-sponsored and corporate debt securities(4)	—	210,669	—	210,669
Total Assets	\$ 88,255	\$ 210,669	\$ 36,344	\$ 335,268
Liabilities				
Convertible senior notes	\$ 302,598	\$ —	\$ —	\$ 302,598
	As of December 31, 2008			
	Level 1	Level 2	Level 3	Balance
Assets				
Auction-rate securities(1)	\$ —	\$ —	\$ 27,976	\$ 27,976
Auction-rate securities put option(2)	—	—	7,685	7,685
Available-for-sale equity investment	97	—	—	97
Money market funds(3)	96,179	—	—	96,179
Federally-sponsored and corporate debt securities(4)	—	209,313	—	209,313
Total Assets	\$ 96,276	\$ 209,313	\$ 35,661	\$ 341,250
Liabilities				
Convertible senior notes	\$ 239,429	\$ —	\$ —	\$ 249,429

(1) Included in non-current marketable investments on the accompanying consolidated balance sheet—refer to the section below entitled *Auction-Rate Securities* for a discussion of the valuation techniques used to estimate the fair value of these securities.

(2) Included within non-current other assets on the accompanying consolidated balance sheet—see the section below entitled *Auction-Rate Securities* for further information regarding the approach used to estimate fair value.

(3) Included in cash and cash equivalents and marketable investments and cash—restricted on the accompanying consolidated balance sheet.

(4) Included in current and non-current marketable investments on the accompanying consolidated balance sheet. The fair value of these securities is derived from pricing models using observable market data including interest rates, yield curves, recently reported trades of comparable securities, credit spreads and benchmark securities. See also Note 5—*Held-to-Maturity Investments*.

A reconciliation of the beginning and ending balances of assets measured at fair value using significant unobservable inputs (Level 3) for the three- and six-month periods ended June 30, 2009, respectively, is presented below (in thousands):

	Auction-rate Securities	Auction-rate Securities Put Option	Total
Balance April 1, 2009	\$ 27,838	\$ 8,177	\$ 36,015
Transfers to (from) Level 3	—	—	—
Total gains/(losses) realized/unrealized included in earnings(1)	212	167	379
Total gains/(losses) included in other comprehensive income	—	—	—
Purchases/issuances/settlements, net	(50)	—	(50)
Balance June 30, 2009	<u>\$ 28,000</u>	<u>\$ 8,344</u>	<u>\$ 36,344</u>

	Auction-rate Securities	Auction-rate Securities Put Option	Total
January 1, 2009	\$ 27,976	\$ 7,685	\$ 35,661
Transfers to (from) Level 3	—	—	—
Total gains/(losses) realized/unrealized included in earnings(1)	74	659	733
Total gains/(losses) included in other comprehensive income	—	—	—
Purchases/issuances/settlements, net	(50)	—	(50)
Balance June 30, 2009	<u>\$ 28,000</u>	<u>\$ 8,344</u>	<u>\$ 36,344</u>

- (1) Gains of \$379,000 and \$733,000 for the three- and six-month periods ended June 30, 2009, respectively, were included in earnings and are attributable to the change in unrealized gains from securities still held at June 30, 2009 (recognized within other income on the consolidated statement of operations).

Auction-Rate Securities

Our marketable investments include AAA-rated, auction-rate securities (ARS) collateralized by student loans that are approximately 91% guaranteed by the federal government. Since February 2008, our ARS have been rendered illiquid as a result of the collapse of the credit markets. Consequently, the fair value of our ARS has been estimated using both a discounted cash flow (DCF) approach and a market comparables method. We consider market data pricing because we believe that it provides relevant information regarding the extent to which similar securities are currently being discounted upon sale. Although the volume of activity within the secondary market for ARS has been increasing, we do not believe such activity occurs with sufficient frequency to rely solely upon such data to determine the fair value of our ARS. As such, we also utilize a DCF model to estimate the fair value of these securities. The key assumptions of the DCF model are subjective and include the following: a reference, or benchmark rate of interest based on the London Interbank Offered Rate (LIBOR), the amounts and timing of cash flows, and the weighted average expected life of a security and its underlying collateral. In addition, the model considers the risks associated with: (i) the creditworthiness of the issuer; (ii) the quality of the collateral underlying the investment; and (iii) illiquidity. The benchmark interest rate is then adjusted upward depending on the degree of risk associated with each security within our auction-rate portfolio. We estimated illiquidity premiums based on an analysis of the average discounts relating to recent sales of comparable ARS within the secondary market.

To mitigate the risks associated with our ARS, we entered into an Auction Rate Securities Rights Offer (Rights Offer) in November 2008 with the investment firm that maintains our ARS account. Pursuant to the Rights Offer, we can sell our ARS to the investment firm for a price equal to their par value (approximately \$36.7 million) at any time between June 30, 2010, and July 2, 2012 (Put Option). To help meet any immediate liquidity needs, the Rights Offer permits us to borrow up to the par value of our ARS; however, we do not expect to exercise this right. The Put Option represents a freestanding, non-transferable financial instrument that is being accounted for under the fair value option set forth in SFAS No.159, *The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No.115* (SFAS 159). Under SFAS 159, all changes in fair value of the Put Option will be recognized within earnings. For the three- and six-month periods ended June 30, 2009, we recognized gains of \$167,000 and \$659,000, respectively, related to the Put Option, which has been included in other income on the consolidated statements of operations. Since there is not an observable market for the Put Option, its fair value has been estimated using significant unobservable inputs; accordingly, it has been categorized as a Level 3 asset within the SFAS 157 hierarchy.

We employed a DCF model to estimate the fair value of the Put Option. We believe that the estimated fair value of the Put Option represents the incremental value associated with the ability to recover the full cost of our ARS at a significantly earlier date than would be otherwise possible, if at all, and the ability to obtain an immediate loan under the Rights Offer, as this right possesses value regardless of whether we expect to borrow under the Rights Offer. Key assumptions used in the DCF model are subjective and include the following: (i) a discount factor equal to the rate of interest consistent with the expected term of the Put Option and risk profile of the investment firm subject to the Put Option; (ii) the amount and timing of expected cash flows; (iii) the expected life of the Put Option prior to its exercise; and (iv) assumed loan amounts. This DCF methodology considered two scenarios. The first scenario assumed that we would borrow up to 50% of the par value of our ARS and the second scenario assumed that we would borrow up to 75% of the par value of our ARS. Under the DCF model, increases in the assumed loan balance would result in an increase in the fair value of the Put Option because the risk of counterparty non-performance diminishes. The estimated fair values generated under both scenarios were given equal weight in estimating the fair value of the Put Option.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable, and accrued expenses approximate fair value because of their short maturities. The fair value of marketable investments is presented in Note 5 and the fair value of notes payable is reported above.

5. Investments

Held-to-Maturity Investments

Marketable investments classified as held-to-maturity consist of the following (in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Government-sponsored enterprises at June 30, 2009	\$ 158,899	\$ 1,256	\$ (8)	\$ 160,147
Corporate notes and bonds at June 30, 2009	50,347	209	(34)	50,522
Total	<u>\$ 209,246</u>	<u>\$ 1,465</u>	<u>\$ (42)</u>	<u>\$ 210,669</u>
As reported on the consolidated balance sheet at June 30, 2009:				
Current marketable securities	\$ 86,361			
Noncurrent marketable securities	122,885			
	<u>\$ 209,246</u>			

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Government-sponsored enterprises at December 31, 2008	\$ 154,115	\$ 1,718	\$ (18)	\$ 155,815
Corporate notes and bonds at December 31, 2008	53,509	140	(151)	53,498
Total	<u>\$ 207,624</u>	<u>\$ 1,858</u>	<u>\$ (169)</u>	<u>\$ 209,313</u>
As reported on the consolidated balance sheet at December 31, 2008:				
Current marketable securities	\$ 106,596			
Noncurrent marketable securities	101,028			
	<u>\$ 207,624</u>			

Certain held-to-maturity investments have been pledged as collateral to Wachovia Development Corporation under the laboratory lease described in Note 10 to these consolidated financial statements, and are classified as restricted marketable investments and cash on our consolidated balance sheets as of June 30, 2009 and December 31, 2008.

Table of Contents

The following table summarizes gross unrealized losses and the length of time marketable investments have been in a continuous unrealized loss position (in thousands):

	As of June 30, 2009		As of December 31, 2008	
	Fair Value	Gross Unrealized Loss	Fair Value	Gross Unrealized Loss
Government sponsored:				
Less than one year	\$ 9,998	\$ (8)	\$ 9,886	\$ (18)
Greater than one year	—	—	—	—
	<u>9,998</u>	<u>(8)</u>	<u>9,886</u>	<u>(18)</u>
Corporate notes:				
Less than one year	\$ 10,835	\$ (34)	\$ 21,278	\$ (151)
Greater than one year	—	—	—	—
	<u>10,835</u>	<u>(34)</u>	<u>21,278</u>	<u>(151)</u>
Total	<u>\$ 20,833</u>	<u>\$ (42)</u>	<u>\$ 31,164</u>	<u>\$ (169)</u>

We attribute the unrealized losses on held-to-maturity securities as of June 30, 2009, to the variability in related market interest rates. We do not intend to sell these securities, nor is it more likely than not that we will be required to sell them prior to the end of their contractual term. Furthermore, we believe these securities do not subject us to undue market risk or counterparty credit risk. As such, we do not consider these securities other-than-temporarily impaired.

The following table summarizes the contractual maturities of held-to-maturity marketable investments at June 30, 2009 (in thousands):

	June 30, 2009	
	Amortized Cost	Fair Value
Due in less than one year	\$ 102,536	\$ 103,474
Due in one to two years	106,710	107,195
Due in three to five years	—	—
Due after five years	—	—
Total	<u>\$ 209,246</u>	<u>\$ 210,669</u>

Trading Investments

Trading securities consist of the following (in thousands):

	Amortized Cost Or Par Value	Cumulative Gross Trading Gains	Cumulative Gross Trading Losses	Cumulative Other Than Temporary Impairment (1)	Estimated Fair Value (2)
Municipal notes (ARS) at June 30, 2009	\$ 36,700	\$ 212	\$ (2,604)	\$ (6,308)	\$ 28,000
Municipal notes (ARS) at December 31, 2008	\$ 36,750	\$ —	\$ (2,466)	\$ (6,308)	\$ 27,976

(1) Recognized during the year ended December 31, 2008.

(2) Included in non-current marketable investments on our consolidated balance sheets.

Equity Investments

We own less than 1% of the common stock of Twin Butte Energy Ltd. (Twin Butte). Our investment in Twin Butte is classified as available-for-sale and reported at fair value based on the quoted market price.

As of June 30, 2009, we maintain an investment totaling approximately \$4.9 million in the preferred stock of a privately held corporation. We account for this investment at cost, as its fair value is not readily determinable. The fair value of our investment has not been estimated at June 30, 2009, as there have been no events or developments that could indicate that the investment may be impaired. This investment is included within non-current other assets on our consolidated balance sheets.

6. Goodwill and Other Intangible Assets

Goodwill and other intangible assets comprise the following (in thousands):

	As of June 30, 2009			As of December 31, 2008		
	Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization	Net
Goodwill	\$ 7,465	\$ —	\$ 7,465	\$ 7,465	\$ —	\$ 7,465
Other intangible assets:						
Technology and patents	4,532	(4,235)	297	4,532	(4,159)	373
Total	<u>\$ 11,997</u>	<u>\$ (4,235)</u>	<u>\$ 7,762</u>	<u>\$ 11,997</u>	<u>\$ (4,159)</u>	<u>\$ 7,838</u>

7. Supplemental Executive Retirement Plan

We maintain the United Therapeutics Corporation Supplemental Executive Retirement Plan (SERP) to provide retirement benefits to certain members of our management team. In connection with the SERP, we maintain the United Therapeutics Corporation Supplemental Executive Retirement Plan Rabbi Trust Document (Rabbi Trust) entered into with the Wilmington Trust Company. The balance in the Rabbi Trust was approximately \$5.1 million as of June 30, 2009 and December 31, 2008. The Rabbi Trust is irrevocable and SERP participants will have no preferred claim on, nor any beneficial ownership interest in, any assets of the Rabbi Trust. The investments in the Rabbi Trust are classified as restricted marketable investments and cash on our consolidated balance sheets.

The table below presents the components of net pension expense (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Service cost	\$ 661	\$ 666	\$ 1,322	\$ 1,224
Interest cost	140	96	280	74
Amortization of prior period service costs	36	36	72	30
Net pension expense	<u>\$ 837</u>	<u>\$ 798</u>	<u>\$ 1,674</u>	<u>\$ 1,328</u>

8. Share Tracking Awards Plan

In June 2008, we adopted the United Therapeutics Corporation Share Tracking Awards Plan (STAP). Awards granted under the STAP (Awards) convey the right to receive in cash an amount equal to the appreciation of our common stock, which is calculated as the positive difference between the closing price of our common stock on the date of exercise and the date of grant. Awards generally vest in one-third increments on each of the first three anniversaries of the date of grant and expire on the tenth anniversary of the date of grant. The STAP does not permit Awards to be settled through the issuance of our common stock.

We account for outstanding Awards as a liability pursuant to FASB Statement No. 123 (revised 2004), *Share-Based Payment* (SFAS 123R), due to their cash-settlement provision. Accordingly, we estimate the fair value of Awards using the Black-Scholes-Merton valuation model at each financial reporting date until settlement occurs or Awards are otherwise no longer outstanding. The STAP liability balance was \$30.1 million and \$8.5 million at June 30, 2009, and December 31, 2008, respectively, and has been included in other current liabilities on our consolidated balance sheets.

In estimating the fair value of Awards, we are required to use inputs that materially impact fair value measurements and the resulting compensation expense recognized. These inputs include the expected volatility of the price of our common stock, the risk-free interest rate, the expected term of Awards, the expected forfeiture rate and the expected dividend yield.

The table below presents the inputs used to re-measure the fair value of Awards at June 30, 2009:

Expected volatility	49.2%
Risk-free interest rate	2.6%
Expected term of Awards (in years)	5.4
Forfeiture rate	5.9%
Expected dividend	0.0%

Presented below is a summary of the activity and status of Awards:

	Number of Awards	Weighted-Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in 000s)
Outstanding at January 1, 2009	1,811,498	\$ 50.64		
Granted	1,106,365	66.47		
Exercised	(12,814)	50.63		
Forfeited	(22,791)	54.55		
Outstanding at June 30, 2009	2,882,258	\$ 56.68	9.3	\$ 76,800
Awards exercisable at June 30, 2009	224,588	\$ 50.63	8.9	\$ 7,344
Awards expected to vest at June 30, 2009	2,487,649	\$ 57.22	9.4	\$ 64,963

The weighted average fair value of Awards granted during the six months ended June 30, 2009, was \$45.34 per Award.

Share-based compensation expense related to the STAP was as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Cost of service sales	\$ 58	\$ 2	\$ 69	\$ 2
Research and development	6,615	314	8,602	314
Selling, general and administrative	9,921	516	12,489	516
Share-based compensation expense before taxes	16,594	832	21,160	832
Related income tax benefits	(4,978)	(308)	(6,348)	(308)
Share-based compensation expense, net of taxes	\$ 11,616	\$ 524	\$ 14,812	\$ 524
Share-based compensation capitalized as part of inventory	\$ 712	\$ 37	\$ 850	\$ 37

We paid approximately \$418,000 in connection with the exercise of Awards during the six months ended June 30, 2009.

9. Debt

Convertible Notes

On October 30, 2006, we issued at par value \$250.0 million of 0.50% Convertible Senior Notes due October 2011 (Convertible Senior Notes). We pay interest on the Convertible Senior Notes semi-annually on April 15 and October 15 of each year. The Convertible Senior Notes are unsecured, unsubordinated obligations that rank equally with all of our other unsecured and unsubordinated indebtedness. The initial conversion price is \$75.2257 per share and the number of shares on which the aggregate consideration is to be determined upon conversion is approximately 3,323,000 shares.

Conversion can occur: (i) anytime after July 15, 2011; (ii) during any calendar quarter that follows a calendar quarter in which the price of our common stock exceeded 120% of the initial conversion price for at least 20 days during the 30 consecutive trading-day period ending on the last trading day of the quarter; (iii) during the ten consecutive trading-day period following any five consecutive trading-day period in which the trading price of the Convertible Senior Notes was less than 95% of the closing price of our common stock multiplied by the then current number of shares underlying the Convertible Senior Notes; (iv) upon specified distributions to our shareholders; (v) in connection with corporate transactions; or (vi) in the event that our common stock ceases to be listed on the NASDAQ Global Select Market (NASDAQ) and is not listed for trading on another U.S. national or regional securities exchange.

Upon conversion, a holder of our Convertible Senior Notes will receive: (i) cash equal to the lesser of the principal amount of the note or the conversion value (equal to the number of shares underlying the Convertible Senior Notes multiplied by the then current conversion price per share); and (ii) to the extent the conversion value exceeds the principal amount of the Convertible Senior Notes, shares of our common stock. In the event of a change in control, as defined in the indenture under which the Convertible Senior Notes have been issued, holders can require us to purchase from them all or a portion of their Convertible Senior Notes for 100% of the principal value plus any accrued and unpaid interest. At June 30, 2009, the aggregate conversion value of the Convertible Senior Notes exceeded their principal value by approximately \$26.9 million using a conversion price of \$83.33, the closing price of our common stock on that date.

Adoption of FSP APB 14-1

On January 1, 2009, we adopted FSP APB 14-1, which applies to certain convertible debt instruments that may be settled in cash or other assets, or partially in cash, upon conversion. Issuers of such convertible debt instruments are required to account for the liability and equity components of these instruments separately in a manner that reflects the issuer's nonconvertible debt borrowing rate when interest expense is subsequently recognized. FSP APB 14-1 requires retrospective application.

The Convertible Senior Notes fall within the scope of FSP APB 14-1 because their terms include partial cash settlement. Pursuant to FSP APB 14-1, we estimated the fair value of the Convertible Senior Notes without the conversion feature as of the date of issuance (Liability Component). The estimated fair value of the Liability Component was approximately \$177.6 million and was determined using a discounted cash flow approach. Key inputs used to estimate the fair value of the Liability Component included the following:

- Our estimated non-convertible borrowing rate as of October 2006—the date the Convertible Senior Notes were issued;
- The amount and timing of cash flows; and
- The expected life of the Convertible Senior Notes.

The excess of the proceeds received over the estimated fair value of the Liability Component totaling \$72.4 million was allocated to the conversion feature (Equity Component) and a corresponding offset was recognized as a discount to reduce the net carrying value of the Convertible Senior Notes. The discount is being amortized to interest expense over a five-year period ending October 2011 (the expected life of the debt) using the interest method and an effective rate of interest of 7.5%.

Interest expense incurred in connection with the Convertible Senior Notes consisted of the following (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Contractual coupon rate of interest	\$ 312	\$ 312	\$ 625	\$ 625
Discount amortization	3,611	3,352	7,155	6,643
Interest expense—Convertible Senior Notes	\$ 3,923	\$ 3,664	\$ 7,780	\$ 7,268

Amounts comprising the carrying amount of the Convertible Senior Notes are as follows (in thousands):

	June 30, 2009	December 31, 2008
Principal balance	\$ 249,978	\$ 249,978
Discount, net of accumulated amortization of \$35,271 and \$28,116	(37,132)	(44,287)
Carrying amount	\$ 212,846	\$ 205,691

The impact of the adoption of FSP APB 14-1 on the results of operations for the three- and six-month periods ended June 30, 2009 and 2008, is presented below (in thousands, except for per share data):

	Three Months Ended June 30, 2009			Three Months Ended June 30, 2008		
	Before the Impact of FSP APB 14-1	Incremental Impact of Adoption of FSP APB 14-1	As Reported	As Previously Reported	Incremental Impact of Adoption of FSP APB 14-1	As Adjusted
Interest expense	\$ —	\$ (3,248)	\$ (3,248)	\$ —	\$ (3,601)	\$ (3,601)
Income tax benefit (expense)	2,214	985	3,199	(8,237)	1,332	(6,905)
Net (loss) income	(81)	\$ (2,263)	(2,344)	14,331	(2,269)	12,062
(Loss) Earnings per share:						
Basic	\$ (0.01)	\$ (0.08)	\$ (0.09)	\$ 0.63	\$ (0.10)	\$ 0.53
Diluted	\$ (0.01)	\$ (0.08)	\$ (0.09)	\$ 0.59	\$ (0.09)	\$ 0.50

	Six Months Ended June 30, 2009			Six Months Ended June 30, 2008		
	Before the Impact of FSP APB 14-1	Incremental Impact of Adoption of FSP APB 14-1	As Reported	As Previously Reported	Incremental Impact of Adoption of FSP APB 14-1	As Adjusted
Interest expense	\$ —	\$ (5,885)	\$ (5,885)	\$ —	\$ (6,285)	\$ (6,285)
Income tax expense	(5,064)	1,465	(3,599)	(14,792)	2,325	(12,467)
Net income	15,275	(4,420)	10,855	25,733	(3,960)	21,733
Earnings per share:						
Basic	\$ 0.58	\$ (0.17)	\$ 0.41	\$ 1.15	\$ (0.18)	\$ 0.97
Diluted	\$ 0.56	\$ (0.16)	\$ 0.40	\$ 1.07	\$ (0.17)	\$ 0.90

The impact of the adoption of FSP APB 14-1 on balance sheet line items as of December 31, 2008, is presented below (in thousands):

	December 31, 2008		
	As Previously Reported	Incremental Impact of Adoption of FSP APB 14-1	As Adjusted
Property, plant and equipment, net	\$ 221,066	\$ 1,651(1)	\$ 222,717
Deferred tax assets—non-current	175,969	2,873	178,842
Other non-current assets	22,974	(1,309)	21,665
Total	\$ 420,009	\$ 3,215	\$ 423,224
Other current liabilities	\$ 16,639	\$ (133)	\$ 16,506
Notes payable, net	249,978	(44,287)	205,691
Total	\$ 266,617	\$ (44,420)	\$ 222,197
Additional paid-in capital	\$ 659,245	\$ 63,048	\$ 722,293
Accumulated deficit	(78,514)	(15,413)	(93,927)
Total	\$ 580,731	\$ 47,635	\$ 628,366

- (1) Additional capitalized interest relating to our construction projects in Maryland and North Carolina resulting from the incremental interest expense recognized upon the retrospective adoption of FSP APB 14-1.

Call Spread Option

Concurrent with the issuance of the Convertible Senior Notes, we purchased call options on our common stock in a private transaction with Deutsche Bank AG London (Call Option). The Call Option allows us to purchase up to approximately 3.3 million shares of our common stock at \$75.2257 per share from Deutsche Bank AG London, which is equal to the amount of our common stock related to the conversion value that we could deliver to holders of the Convertible Senior Notes upon conversion. We will be required to issue shares of our common stock upon conversion if the price of our common stock exceeds \$75.2257 per share at

conversion. The Call Option will terminate upon the earlier of the maturity date of the Convertible Senior Notes or the first day all of the Convertible Senior Notes are no longer outstanding due to conversion or otherwise. We paid approximately \$80.8 million for the Call Option, which was recorded as a reduction to additional paid-in-capital.

In a separate transaction that took place simultaneously with the issuance of the Convertible Senior Notes, we sold warrants to Deutsche Bank AG London under which Deutsche Bank AG London has the right to purchase approximately 3.3 million shares of our common stock at an exercise price of \$105.689 per share (Warrant). Proceeds received from the Warrant totaled approximately \$45.4 million and were recorded as additional paid-in-capital.

The shares deliverable to us under the Call Option must be obtained from existing shareholders. Any shares that we may be required to deliver under the Warrant can consist of registered or unregistered shares, subject to potential adjustments to the settlement amount. The maximum number of shares of our common stock that we may be required to deliver in connection with the Warrant is approximately 6.6 million. We have reserved approximately 6.6 million shares for the settlement of the Warrant and have sufficient shares available as of June 30, 2009, to effect such settlement.

The combination of the Call Option and Warrant effectively reduces the potential dilutive impact of the Convertible Senior Notes. The Call Option has a strike price equal to the initial conversion price of the Convertible Senior Notes and the Warrant has a higher strike price of \$105.689 per share that caps the amount of dilution protection provided. The Call Option and Warrant can be settled on a net share basis.

In accordance with the provisions of Emerging Issues Task Force (EITF) Issue No. 00-19, *Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock* (EITF 00-19), and SFAS No. 133, *Accounting for Derivatives and Hedging Activities* (SFAS 133), these instruments are both indexed to our common stock and classified as equity; therefore, the Call Option and Warrant qualify for the scope exception under SFAS 133 and are not accounted for as derivative instruments.

Interest Expense

Details of interest expense for the three- and six-month periods ended June 30, 2009 and 2008, are presented below (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Interest expense	\$ 4,164	\$ 4,546	\$ 8,877	\$ 7,230
Capitalized interest	(916)	(945)	(2,992)	(945)
Total interest expense	\$ 3,248	\$ 3,601	\$ 5,885	\$ 6,285

10. Lease Obligation

We lease our laboratory facility in Silver Spring, Maryland (Phase I Laboratory), pursuant to a synthetic lease arrangement (Lease) entered into in June 2004 with Wachovia Development Corporation and its affiliates (Wachovia). Under the Lease, Wachovia funded \$32.0 million toward the construction of the Phase I Laboratory on land we own. Subsequent to the completion of construction in May 2006, Wachovia leased the Phase I Laboratory to us. Monthly rent is equal to the 30-day LIBOR plus 55 basis points (0.86% as of June 30, 2009) applied to the amount Wachovia funded toward construction. The base term of the Lease ends in May 2011 (Base Term). Upon the end of the Base Term, we will have the right to exercise one of the following options under the Lease: (i) renew the lease for an additional five-year term (subject to the approval of both parties); (ii) purchase the Phase I Laboratory from Wachovia for approximately \$32.0 million; or (iii) sell the Phase I Laboratory and repay Wachovia's construction costs with the proceeds from the sale. If the sale proceeds are insufficient to repay Wachovia's construction costs, we must fund the shortfall up to the maximum residual value guarantee of approximately \$27.5 million. From the inception of the Lease through August 2008, we accounted for the Lease as an operating lease.

Since December 2007, we have been constructing a combination office and laboratory facility that will attach to the Phase I Laboratory (Phase II Facility) with funds generated from our operations. As of September 30, 2008, we received Wachovia's acknowledgement of our plan to make structural modifications to the Phase I Laboratory in order to connect it to the Phase II Facility. As a result, we could no longer consider the Phase I Laboratory a standalone structure, which was required to maintain off-balance sheet accounting for the Lease. Consequently, as of September 30, 2008, we were considered the owners of the Phase I Laboratory for accounting purposes and are accounting for the Lease as a financing obligation. Accordingly, we capitalized \$29.0 million, the estimated fair value of the Phase I Laboratory, and recognized a corresponding lease obligation on our consolidated balance sheet. We are accreting the lease obligation to \$32.0 million, the purchase price of the Phase I Laboratory, through the recognition of periodic

interest charges using the effective interest method. The accretion period will run through the end of the Base Term. Related interest charges for the three- and six-month periods ended June 30, 2009, were approximately \$265,000 and \$528,000, respectively. In addition, we are depreciating the Phase I Laboratory over the estimated useful lives of its various components.

11. Stockholders' Equity

(Loss) earnings per share

Earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if such securities were converted or exercised. Basic and diluted loss per share are computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period as the impact of potentially dilutive securities would be anti-dilutive.

The components of basic and diluted (loss) earnings per share is presented below (in thousands, except per share amounts):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Net (loss) income (numerator)	\$ (2,344)	\$ 12,062	\$ 10,855	\$ 21,773
Shares (denominator):				
Weighted average outstanding shares for basic EPS	26,491	22,600	26,466	22,467
Convertible Senior Notes(1)	—	572	—	522
Dilutive effect of stock options(2)	—	1,156	877	1,131
Adjusted weighted average shares for diluted EPS	26,491	24,328	27,343	24,120
(Loss) earnings per share				
Basic	\$ (0.09)	\$ 0.53	\$ 0.41	\$ 0.97
Diluted	\$ (0.09)	\$ 0.50	\$ 0.40	\$ 0.90
Stock options and warrants excluded from calculation(3)	7,967	4,554	3,812	4,504

(1) Pursuant to FASB Statement No. 128, *Earnings per Share*, and related guidance, we cannot consider the impact of shares that we could receive under the terms of the Call Option (see Note 9 — *Debt — Call Spread Option* to these consolidated financial statements) in the calculation of diluted earnings per share as their impact would be anti-dilutive. For the three- and six-month periods ended June 30, 2009 and 2008, the effects of the Call Option would have offset the dilutive impact of the Convertible Senior Notes.

(2) Calculated using the treasury stock method.

(3) Certain stock options, warrants and shares potentially issuable upon conversion of the Convertible Senior Notes were excluded from the computation of diluted earnings per share because their impact would be anti-dilutive.

Stock Option Plan

We account for stock option awards in accordance with SFAS 123R, as interpreted by Staff Accounting Bulletins Nos. 107 and 110 issued by the SEC. Accordingly, we utilize the Black-Scholes-Merton valuation model for estimating the fair value of stock option awards as of their grant dates. Option valuation models, including Black-Scholes-Merton, require the input of subjective assumptions. Changes in these assumptions can materially affect the grant date fair value of an award.

Table of Contents

Presented below are the weighted average assumptions used to estimate the fair value of stock options granted during the three- and six-month periods ended June 30, 2009 and 2008:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Expected volatility	49.1%	42.31%	49.1%	42.29%
Risk-free interest rate	2.2%	3.1%	2.2%	3.1%
Expected term of options (years)	5.5	5.5	5.5	5.6
Expected dividend yield	0.0%	0.0%	0.0%	0.0%
Forfeiture rate	0.0%	5.6%	0.0%	5.6%

Presented below is a summary of the activity and status of employee stock options:

	Number of Shares	Weighted- Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in 000s)
Outstanding at January 1, 2009	4,586,691	\$ 54.75		
Granted	83,750	76.55		
Exercised	(144,994)	42.15		
Forfeited	(13,895)	62.09		
Outstanding at June 30, 2009	4,511,552	\$ 55.55	6.6	\$ 125,380
Options exercisable at June 30, 2009	2,529,208	\$ 51.11	5.6	\$ 81,484
Expected to vest at June 30, 2009	1,904,564	\$ 61.23	7.9	\$ 42,085

Employee share-based compensation expense related to stock options was as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Cost of service sales	\$ 12	\$ 14	\$ 25	\$ 29
Research and development	2,318	2,401	4,987	5,070
Selling, general and administrative	15,441	3,839	22,248	7,447
Share-based compensation expense before taxes	17,771	6,254	27,260	12,546
Related income tax benefits	(5,331)	(2,314)	(8,178)	(4,642)
Share-based compensation expense, net of taxes	\$ 12,440	\$ 3,940	\$ 19,082	\$ 7,904
Share-based compensation capitalized as part of inventory	\$ 273	\$ 261	\$ 499	\$ 456

Employee and non-employee stock-option exercise data is summarized below (dollars in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Number of options exercised	124,773	264,487	144,994	499,804
Cash received	\$ 5,255	\$ 9,437	\$ 6,112	\$ 18,003

12. Comprehensive Income

For the three- and six-month period ended June 30, 2009 and 2008, comprehensive income comprised the following (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Net (loss) income	\$ (2,344)	\$ 12,062	\$ 10,855	\$ 21,773
Other comprehensive income:				
Foreign currency translation gain (loss)	4,015	(206)	3,111	(356)
Unrecognized prior period pension service cost, net of tax	24	23	46	(461)
Unrecognized actuarial pension loss, net of tax	—	—	—	(227)
Unrealized gain (loss) on available-for-sale securities, net of tax	42	(184)	29	(1,300)
Comprehensive income	\$ 1,737	\$ 11,695	\$ 14,041	\$ 19,429

13. Income Taxes

The income tax benefit and income tax expense for the three- and six-month periods ended June 30, 2009 and 2008, is based on the estimated annual effective tax rate. The estimated annual effective tax rate can be adjusted in subsequent quarterly reporting periods as projections of pre-tax income for the year are revised. The effective tax rates for the three- and six-month periods ended June 30, 2009, were approximately 58 percent and 25 percent, respectively, and the effective tax rates for both the three- and six-month periods ended June 30, 2008, were approximately 37 percent. The effective tax rate for the three months ended June 30, 2009, was driven in large part by the recognition of a pre-tax loss for the quarter and a decrease in the estimated annual effective tax rate from the quarter ended March 31, 2009. The decrease in the estimated annual effective tax rate for the six months ended June 30, 2009, principally corresponded to a reduction in projections of pre-tax income for 2009.

As of June 30, 2009, we had available for federal income tax purposes approximately \$67.3 million in business tax credit carryforwards that will expire at various dates through 2028. Certain business tax credit carryforwards that were generated prior to December 2007 may be subject to limitations on their use pursuant to Internal Revenue Code Section 382 as a result of ownership changes as defined therein. However, we do not expect these business tax credits to expire unused.

We file U.S. federal income tax returns and various state and foreign income tax returns. All of our U.S. federal income tax returns remain open for examination since we have not utilized any of our business tax credits. State jurisdictions that remain subject to examination relate to our filings for the years 2005 through 2007. We are unaware of any uncertain tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits would significantly increase or decrease within the next twelve months.

14. Segment Information

We have two reportable business segments: pharmaceutical and telemedicine. The pharmaceutical segment includes all activities associated with the research, development, manufacturing and commercialization of our therapeutic products. The telemedicine segment includes all activities associated with the development and manufacturing of patient monitoring products and the delivery of patient monitoring services. The telemedicine segment is managed separately because diagnostic services require different technologies and marketing strategies than therapeutic products.

Summarized segment information is presented below (in thousands):

	As of, and for the Three Months Ended June 30,					
	2009			2008		
	Pharmaceutical	Telemedicine	Consolidated Totals	Pharmaceutical	Telemedicine	Consolidated Totals
Revenues from external customers	\$ 81,281	\$ 2,699	\$ 83,980	\$ 66,104	\$ 2,452	\$ 68,556
(Loss) income before income tax	(5,625)	82	(5,543)	18,779	188	18,967
Total assets	932,775	18,896	951,671	665,399	13,006	678,405

	As of, and for the Six Months Ended June 30,					
	2009			2008		
	Pharmaceutical	Telemedicine	Consolidated Totals	Pharmaceutical	Telemedicine	Consolidated Totals
Revenues from external customers	\$ 158,441	\$ 5,269	\$ 163,710	\$ 125,861	\$ 4,742	\$ 130,603
Income (loss) before income tax	14,512	(58)	14,454	33,860	380	34,240
Total assets	932,775	18,896	951,671	665,399	13,006	678,405

When combined, the segment information above agrees with the totals reported in the consolidated financial statements. There are no inter-segment transactions.

For the three-month periods ended June 30, 2009 and 2008, revenues from our three U.S.-based distributors represented approximately 85 percent and 84 percent, respectively, of our total net revenues. For the six-month periods ended June 30, 2009 and 2008, revenues from our three U.S.-based distributors represented approximately 85 percent and 84 percent, respectively, of our total net revenues.

15. Legal proceedings

On May 7, 2009, purported shareholder Jeffrey Benison IRA filed a derivative complaint in the Court of Chancery for the State of Delaware against each of our directors other than our newly-appointed director, Richard Giltner, and us as nominal defendant. The lawsuit is captioned *Jeffrey Benison IRA v. Causey, et al.*, Civil Action No. 4569-CC. The complaint, which the plaintiff purports to bring on our behalf, alleges among other things that the named director defendants breached their fiduciary duty of loyalty and committed waste in connection with the adoption of our STAP in June 2008 and the late 2008 modification of Awards and repricing of certain stock options granted under our Amended and Restated Equity Incentive Plan. The plaintiff is seeking unspecified monetary damages purportedly for United Therapeutics Corporation, as well as attorneys' fees and costs, and injunctive relief, including revocation and/or revision of the STAP. We believe the plaintiff's allegations are without merit and we intend to defend against these claims vigorously. Furthermore, we have been advised that the individual director defendants also intend to defend against these claims vigorously.

On July 28, 2009, another purported shareholder, the Retirement Board of Allegheny County, filed a complaint in the Court of Chancery for the State of Delaware against us. The lawsuit, captioned *Retirement Board of Allegheny County v. United Therapeutics Corporation*, Civil Action No. 4764, seeks an order allowing the plaintiff to inspect our records relating principally to the same issues addressed in the complaint filed by Jeffrey Benison IRA, as well as attorneys' fees and costs.

From time to time, we may be involved in other lawsuits and proceedings incidental to the conduct of our business. Presently, we are not a party to any other lawsuit or proceeding that, in the opinion of our management, is likely to have a material adverse effect on our financial position or results of operations.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2008, and the consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q. The following discussion contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, including the statements listed in the section entitled *Part II, Item 1A—Risk Factors*, below. These statements are based on our beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause actual results to differ materially from anticipated results. Factors that could cause or contribute to such differences include those described under the section entitled *Risk Factors* in *Part II, Item 1A* of this Quarterly Report on Form 10-Q; factors described in our Annual Report on Form 10-K for the year ended December 31, 2008, under the section entitled *Part I, Item 1A—Risk Factors—Forward-Looking Statements*; and factors described in other cautionary statements, cautionary language and risk factors set forth in other filings with the Securities and Exchange Commission (SEC). We undertake no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

We are a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Our key therapeutic platforms include:

- Prostacyclin analogues: stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function;
- Phosphodiesterase 5 (PDE-5) inhibitors: molecules that act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. cGMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle;
- Monoclonal antibodies: antibodies that activate patients' immune systems to treat cancer; and
- Glycobiology antiviral agents: a novel class of small, sugar-like molecules that have shown pre-clinical indications of efficacy against a broad range of viruses.

We devote most of our resources to these key therapeutic platforms. In addition, we allocate resources to the commercialization and development of telemedicine products and services, principally for the detection of cardiac arrhythmias (abnormal heart rhythms).

Our lead product is Remodulin[®] (treprostinil sodium) Injection (Remodulin) to be administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension (PAH). The United States Food and Drug Administration (FDA) initially approved Remodulin in 2002 for subcutaneous (under the skin) administration. Subsequently, the FDA broadened its approval of Remodulin for intravenous (in the vein) use and for the treatment of patients who require transition from Flolan[®], the first drug approved by the FDA for the treatment of PAH. In addition to the United States, Remodulin is approved in many other countries, primarily for subcutaneous use. Currently, our core initiatives include the commercialization of Adcirca[™] (tadalafil) tablets, an orally administered therapy for the treatment of pulmonary hypertension to which we acquired certain exclusive commercialization rights from Eli Lilly & Company (Lilly) in November 2008 and Tyvaso[™] (treprostinil) Inhalation Solution for the treatment of PAH. In addition, we are continuing to develop an oral formulation of treprostinil.

Revenues

We derive substantially all of our revenues from sales of Remodulin. Our distributors, Accredo Therapeutics, Inc. (Accredo), CuraScript, Inc. (CuraScript), and CVS Caremark (Caremark), sell Remodulin to patients in the United States. We also engage distributors in other countries to sell Remodulin abroad. Because discontinuation of Remodulin therapy can be life threatening, we require our distributors to maintain minimum contingent inventory levels; consequently, sales of Remodulin to our distributors in any given quarter may not be entirely indicative of patient demand. Our distributors typically place one bulk order per month based on their estimates of future demand and considerations of contractual minimum inventory requirements. As such, our sales of Remodulin can be affected by the timing and magnitude of distributor orders.

Table of Contents

Other sources of revenue include the sale of telemedicine products and services in the United States. Our telemedicine products and services are designed to detect cardiac arrhythmias and ischemic heart disease, a condition that causes poor blood flow to the heart.

We operate in a highly competitive market. For instance, a small number of pharmaceutical companies control most of the current PAH therapies that are approved for use. There are also a number of investigational products currently in development that, once approved, may erode the market share of existing commercial therapies. Competing therapies may have a significant impact on the success of our sales force and, ultimately, our sales. We expect that the competition within our industry will continue to increase.

Expenses

Since our inception, we have devoted substantial resources toward our various research and development initiatives. Accordingly, we incur considerable costs relating to our clinical trials and research, conducted both internally and by third parties, on a variety of projects to develop pharmaceutical therapies. We also seek to license or acquire promising technologies and/or compounds to be incorporated into our developmental projects.

Major Research and Development Projects

Our major research and development projects focus on the use of prostacyclin analogues and PDE-5 inhibitors to treat cardiovascular diseases, monoclonal antibodies to treat a variety of cancers, and glycobiology antiviral agents to treat infectious diseases.

Cardiovascular Disease Projects

Tyvaso. In November 2007, we completed a Phase III clinical trial of Tyvaso in patients with PAH who were also being treated with either Tracleer[®], an oral endothelin receptor antagonist (ERA), or Revatio[®], a PDE-5 inhibitor. This clinical trial, called TRIUMPH-1, demonstrated a highly statistically significant improvement in median six-minute walk distance, the endpoint primarily used to measure improvement in PAH patients.

Based on the favorable results of TRIUMPH-1, we submitted a New Drug Application (NDA) in June 2008 to obtain FDA approval to market Tyvaso in the United States. The Optineb[®] nebulizer, an ultra-sonic portable nebulizer that was exclusively used for administration of Tyvaso during TRIUMPH-1, was submitted for approval as part of this filing. The Optineb is manufactured by NEBU-TEC International Med Products Eike Kern GmbH (NEBU-TEC). The Optineb is CE-marked in Europe, which means that NEBU-TEC has asserted that the device conforms to European Union health and safety requirements. In December 2008, we executed an agreement with NEBU-TEC to acquire the Optineb business and all its related assets, properties and rights for an aggregate purchase price of €5.0 million, plus up to €10.0 million in future contingent payments. In addition, we filed a Marketing Authorization Application (MAA) in December 2008 for Tyvaso with the European Medicines Agency (EMA) using the centralized filing process. The Optineb was also included as part of our MAA submission. The duration of a typical review of an NDA or MAA is approximately 10 to 12 months, but can take significantly longer.

In March 2009, the FDA notified us that it required human factors testing to validate the instructions for use (IFU) for the Tyvaso Inhalation System in order to complete its evaluation of our Tyvaso NDA. Accordingly, we conducted a human factors study to assess whether the revised IFU properly guided patients to accomplish the tasks necessary for the correct use and maintenance of the Tyvaso Inhalation System. Findings of this study were submitted to the FDA in April 2009. Subsequently, the FDA notified us that it would require additional time to complete its review of our NDA and extended the Prescription Drug User Fee Act (PDUFA) date to July 30, 2009.

On July 30, 2009, the FDA approved Tyvaso (treprostinil) Inhalation Solution for the treatment of PAH using the Tyvaso Inhalation System (which includes the Optineb-ir device and accessories). Tyvaso is indicated to increase walk distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease. In connection with the Tyvaso approval, we have agreed to a post-marketing requirement (PMR) and certain post-marketing commitments (PMC). Post-marketing requirements and post-marketing commitments are studies and clinical trials that sponsors conduct after FDA approval to gather additional information about a product's safety, efficacy, or optimal use. Some of these studies and clinical trials may be required (PMR); others may be studies or clinical trials that a sponsor has committed to conduct (PMC). We are required to provide FDA updates on our PMR and PMCs annually. Failure to complete the studies or adhere to the timelines set by the FDA could result in penalties, including fines or withdrawal of Tyvaso from the market, unless we are able to demonstrate good cause for not completing the studies or adhering to our timelines.

In accordance with the PMR, we will conduct a long-term observational study in the U.S. that will include 1,000 patient-years of follow-up in Tyvaso-treated patients, and 1,000 patient-years of follow-up in matched control patients receiving other PAH treatments to evaluate the potential association between Tyvaso and oropharyngeal and pulmonary toxicity. We have committed to submitting the results of this study to the FDA by December 15, 2013.

The PMC requires us to re-engineer the Tyvaso Inhalation System in the following ways: (i) create a titratable breath counter; (ii) align/key the dome of the device; (iii) add a battery back-up power pack; and (iv) permanently fix the baffle plate to the dome. As part of the re-engineering process, we have also agreed to perform a usability analysis incorporating the evaluation and prioritization of user-related risk followed by a human factors study, and we will conduct a study in healthy volunteers to collect pharmacokinetic data to verify expected dosing with the re-engineered device. We have committed to submit a Supplement to our Tyvaso NDA describing the results of this study no later than October 31, 2010.

In December 2008 we began enrolling patients in an open-label study in the United States to investigate what occurs when patients on Ventavis[®], the only currently approved inhaled prostacyclin analogue, are switched to Tyvaso.

Tadalafil. In November 2008, we entered into several related agreements with Lilly to license certain exclusive rights to the orally administered drug, tadalafil. Tadalafil is the active ingredient in Cialis[®], a therapy developed and exclusively marketed by Lilly for the treatment of erectile dysfunction. We paid upfront fees to Lilly totaling \$150.0 million for the exclusive rights to commercialize tadalafil for

the treatment of pulmonary hypertension in the United States and Puerto Rico. In addition, we will purchase tadalafil from Lilly in finished form and Lilly will distribute tadalafil for us through its wholesaler network. Our agreements

with Lilly became effective in December 2008 upon the issuance of approximately 3.2 million shares of our common stock to Lilly in exchange for \$150.0 million. In May 2009, the FDA approved tadalafil for the treatment of PAH. Tadalafil will be marketed under the brand name Adcirca and commercial launch will occur in August 2009. Upon receiving FDA approval, Lilly was granted orphan drug exclusivity for tadalafil for a period of seven years. During this exclusivity period, the FDA may not approve any application to market the same drug for the same indication, except in limited circumstances.

Oral treprostinil. In December 2006, we initiated two clinical trials, FREEDOM-C and FREEDOM-M, to evaluate the safety and efficacy of oral treprostinil in patients with PAH.

The FREEDOM-C clinical trial was a study of patients currently on approved background therapy using a PDE-5 inhibitor, such as Revatio[®], or an ERA, such as Tracleer[®], or a combination of both. We completed enrollment for FREEDOM-C in May 2008 and in November 2008, we announced that FREEDOM-C failed to achieve statistical significance. Preliminary analysis of the data revealed that the initial tablet strength was too high, which contributed to an inability to dose titrate (increase the dose to tolerability) and prevented the attainment of optimal dosing levels. Consequently, the overall treatment effect of the therapy was muted. However, we believe that the results of the FREEDOM-C clinical trial, particularly as they relate to treatment effect and dosing, support our continued development of oral treprostinil. Accordingly, we commenced a second clinical trial, FREEDOM-C², to continue studying dosage and efficacy of oral treprostinil in PAH patients on approved background therapy. Enrollment in FREEDOM-C² began in June 2009.

The FREEDOM-M clinical trial is a 12-week study of newly-diagnosed PAH patients not currently on any background therapy. Based on our observations from the FREEDOM-C clinical trial relating to patient tolerability and tablet strength, we submitted a protocol amendment to the FDA in February 2009 seeking to add patients to the ongoing FREEDOM-M trial. These additional patients will be provided a lower-strength tablet (0.25 mg) when they begin the trial and their doses will be titrated in 0.25 mg increments, which we believe will improve tolerability. In addition, our amendment to the FREEDOM-M protocol seeks to limit the primary statistical analysis of the trial to only those patients who started the trial using the 0.25 mg tablet. In amending FREEDOM-M we hope to achieve the following objectives: (i) to assess more accurately the effectiveness of oral treprostinil; (ii) to improve patient tolerability of oral treprostinil so that an effective maintenance dose can be attained; and (iii) to reduce the rate of premature discontinuation due to adverse events. The statistical assumptions of the amended protocol provide for 90% power to observe a 45 meter treatment benefit in six-minute walk distance at the significance level of 0.01. If we are able to successfully implement these protocol amendments, we believe that the results will reflect the expected dosing regimen for oral treprostinil. In April 2009, we began enrolling patients in FREEDOM-M under the amended protocol.

Beraprost-MR. Pursuant to our license agreement with Toray Industries, Inc. (Toray), we are developing a modified release formulation of beraprost (beraprost-MR), an oral prostacyclin analogue, for the treatment of PAH. Currently, we are enrolling patients in a Phase II clinical trial of beraprost-MR to explore multiple-dose tolerability in patients with PAH and are planning further clinical development intended to evaluate the efficacy of beraprost-MR for the treatment of PAH. In October 2007, beraprost-MR received regulatory approval in Japan for the treatment of PAH, and in July 2008 beraprost-MR was granted Orphan Medicinal Product Designation by the EMEA.

From inception to June 30, 2009, we have spent approximately \$478.4 million on cardiovascular programs.

Cancer Disease Projects

In December 2007, we entered into two agreements with Memorial Sloan-Kettering Cancer Center to license certain rights to two investigational monoclonal antibodies (3F8 and 8H9) for the treatment of neuroblastoma and metastatic brain cancer. We have been granted orphan drug exclusivity in the United States and received a positive opinion from the committee on orphan medicinal products in the European Union (EU) for the use of the 3F8 monoclonal antibody for the treatment of neuroblastoma. We have spent approximately \$60.4 million from inception to June 30, 2009, on this and earlier programs in our cancer platform.

Infectious Disease Projects

Pursuant to our research agreement with the University of Oxford, we have the exclusive right to commercialize miglustat as an antiviral agent for the treatment of all sugarcoated viruses. Our infectious disease program also includes glycobiology antiviral drug candidates in various preclinical and clinical stages of testing for the treatment of a wide variety of viruses. Through our research agreement with the University of Oxford, we are also supporting research into new glycobiology antiviral drug candidates and technologies. We have spent approximately \$40.1 million from inception to June 30, 2009, on our infectious disease programs.

Cost of Product Sales

Cost of product sales comprises costs to manufacture or acquire products sold to customers. We manufacture treprostinil using advanced intermediate compounds purchased in bulk from several third-party vendors who have the capacity to produce greater quantities of these compounds more cost effectively than we do. In May 2009, we received FDA approval to produce treprostinil in our Silver Spring, Maryland, laboratory facility (Phase I Laboratory). International regulatory approval for our Phase I Laboratory is currently pending. Our planned manufacturing process has been designed to give us the flexibility to produce both treprostinil diethanolamine (the form of treprostinil used in our oral tablet) and treprostinil (used to produce inhaled and parenteral formulations) efficiently in proportion to forecasted demand.

We are also evaluating alternative supply arrangements, including other third-party production arrangements and the formulation of Remodulin in our combination office and laboratory facility that we are currently constructing in Silver Spring, Maryland. During the second half of 2009, we expect to increase our supply of formulated Remodulin to three years of expected demand to ensure we maintain adequate inventory at all times. In conjunction with this projected increase in inventory, we obtained FDA approval extending the shelf life of Remodulin from 30 months to 36 months and are currently seeking similar approval from the EMEA.

Future Prospects

Because PAH is a progressive disease without a cure, many patients continue to deteriorate on currently approved therapies. This presents market growth opportunities for Remodulin, Tyvaso and Adcirca (our commercial products) as viable alternatives or complementary treatments to existing therapies. Furthermore, we anticipate that the market for our commercial products will continue to expand as more patients are diagnosed with PAH each year. We have experienced annual revenue growth in excess of 30 percent since Remodulin was first approved in 2002. One of our principal objectives is to maintain this level of growth. The continued achievement of this objective will depend upon the success of our commercial development of products within our pipeline and our ability to treat more PAH patients. To this end, we are seeking to expand the use of our therapies to treat patients at earlier stages in the PAH disease pathway. These efforts currently include our commercial launch of Adcirca in August 2009, our expected launch of Tyvaso in September 2009, and the continued development of oral treprostinil. In connection with the commercial launch of Tyvaso, we may enter into new distribution agreements in selected markets worldwide.

We believe the outcome of our FREEDOM-M and FREEDOM-C² clinical trials of oral treprostinil will be successful. Furthermore, we believe that the products developed under these clinical trials will generate future sources of revenue. However, prior to FDA approval of oral treprostinil for marketing, we could be required to perform additional studies. This could cause unexpected delays in the commercialization of these products and could impede our anticipated revenue growth. Our future growth and profitability will depend on many factors. These factors include, among others, the timing and outcome of clinical trials and regulatory approvals, including the PMC and PMR relating to the FDA's approval of Tyvaso, the timing of commercial launch of new products, the pricing of and demand for our products and services, reimbursement of our products by public and private insurance organizations, and the competition we face from within our industry.

Financial Position

Cash, cash equivalents and marketable investments (excluding all restricted amounts) were \$350.7 million at June 30, 2009, compared to \$336.3 million as of December 31, 2008. The increase in cash and marketable investments was driven mainly by: (i) continued sales growth and related cash receipts from sales of Remodulin; (ii) the reduction in construction-related expenditures as we completed the construction of our facility in Research Triangle Park, North Carolina, during the first quarter of 2009; and (iii) \$6.1 million received in proceeds from the exercise of stock options during the six-month period ended June 30, 2009.

Restricted cash and marketable investments of \$46.2 million at June 30, 2009, comprise \$41.1 million pledged as security for our Phase I Laboratory and \$5.1 million placed in the United Therapeutics Corporation Supplemental Executive Retirement Plan Rabbi Trust Document (Rabbi Trust). At December 31, 2008, approximately \$40.7 million was pledged as security for our Phase I Laboratory and approximately \$5.1 million was placed in the Rabbi Trust.

Accounts receivable was \$34.4 million at June 30, 2009, compared to \$28.3 million at December 31, 2008. The growth in accounts receivable corresponded to an increase in Remodulin sales of 11% for the quarter ended June 30, 2009, compared to the quarter ended December 31, 2008, and to the customary variances in the timing of sales and related cash receipts.

Property, plant and equipment at June 30, 2009, was \$283.0 million, an increase of \$60.3 million from \$222.7 million at December 31, 2008. The increase was driven by expenditures for our construction projects in Maryland and North Carolina during the six-month period ended June 30, 2009. Construction of the North Carolina facility was completed in February 2009.

Other current liabilities increased by \$15.9 million from \$16.5 million at December 31, 2008, to \$32.4 million at June 30, 2009. Since December 31, 2008, our liability for the United Therapeutics Corporation Share Tracking Awards Plan (STAP) has increased by approximately \$21.6 million primarily as a result of the appreciation in the price of our common stock. The increase in STAP liability was partially offset by a \$5.3 million reduction in taxes payable which resulted from estimated tax payments and the recognition of tax benefits associated with stock option exercises during the first half of 2009.

As of June 30, 2009, convertible senior notes increased by \$7.1 million, from \$205.7 million at December 31, 2008, to \$212.8 million at June 30, 2009. The increase resulted from the amortization of the debt discount for the six-month period ended June 30, 2009. See Note 9 to the consolidated financial statements included in this Quarterly Report on Form 10-Q for further discussion.

Additional paid-in capital was \$757.9 million at June 30, 2009, compared to \$722.3 million at December 31, 2008. The increase of \$35.6 million can be attributed principally to the recognition of \$27.8 million in share-based compensation and the receipt of \$6.1 million in proceeds from the exercise of stock options during the six-month period ended June 30, 2009.

Results of Operations

Three months ended June 30, 2009 and 2008

The following table sets forth the components of net revenues (dollars in thousands):

	Three Months Ended		% Change
	2009	June 30, 2008	
Remodulin	\$ 80,954	\$ 65,427	23.7%
Telemedicine services and products	2,699	2,451	10.1%
Distributor fees	323	666	(51.5)%
Other products	4	12	(66.7)%
Total revenues	\$ 83,980	\$ 68,556	22.5%

The growth in revenues for the three months ended June 30, 2009, corresponded in large part to the continued increase in the number of patients being prescribed Remodulin. For the three months ended June 30, 2009 and 2008, approximately 89 percent and 88 percent of net Remodulin revenues were derived from our three U.S.-based distributors.

Total revenues are reported net of estimated government rebates, prompt pay discounts and fees due to our distributors for services. We pay government rebates to state Medicaid agencies that pay for Remodulin. We estimate our liability for these rebates based on the historical level of government rebates invoiced by state Medicaid agencies relative to sales of Remodulin in the United States. Prompt pay discounts are offered on sales of Remodulin if the related invoices are paid in full, generally within 60 days from the date of sale. We estimate our liability for prompt pay discounts based on historical payment patterns. Fees paid to our distributors for services are estimated based on contractual rates for specific services applied to the estimated units of service provided by our distributors for the period.

Table of Contents

The table below presents a reconciliation of the liability accounts associated with estimated government rebates, prompt pay discounts and fees to our distributors for services and the net reductions to revenues related to these items (dollars in thousands):

	Three Months Ended June 30,	
	2009	2008
Liability accounts, at beginning of period	\$ 4,178	\$ 3,450
Additions to liability attributed to sales in:		
Current period	3,893	3,518
Prior period	—	—
Payments or reductions attributed to sales in:		
Current period	(3,182)	(3,560)
Prior period	(1,255)	—
Liability accounts, at end of period	\$ 3,634	\$ 3,408
Net reductions to revenues	\$ 3,893	\$ 3,518

The table below summarizes research and development expense by significant component (dollars in thousands):

Program:	Three Months Ended June 30,		Percentage Change
	2009	2008	
Cardiovascular	\$ 13,105	\$ 11,890	10.2%
Other	6,608	3,938	67.8%
Share-based compensation	8,933	3,313	169.6%
Total research and development expense	\$ 28,646	\$ 19,141	49.7%

Cardiovascular. Expenses incurred in connection with the commencement of the amended FREEDOM-M clinical trial and the new FREEDOM-C² clinical trial during the three-month period ended June 30, 2009, resulted in an increase of approximately \$1.6 million in related cardiovascular expenses when compared to the quarter ended June 30, 2008.

Other. The increase in other research and development expenses of approximately \$2.7 million during the three-month period ended June 30, 2009, compared to the three-month period ended June 30, 2008, corresponded mainly to an increase in our investigational projects, including those within our glycobiology antiviral agent therapeutic platform.

Share-based compensation. The increase in share-based compensation expense of \$5.6 million for the three-month period ended June 30, 2009, compared to the quarter ended June 30, 2008, can be attributed to the following: (i) the increase in the fair value of awards granted under the STAP as the result of the appreciation in the price of our common stock; and (ii) increases in the number of outstanding STAP awards, and the time that these awards have accrued toward vesting at June 30, 2009.

The table below summarizes selling, general and administrative expense by major category (dollars in thousands):

Category:	Three Months Ended June 30,		Percentage Change
	2009	2008	
General and administrative	\$ 12,960	\$ 9,444	37.2%
Sales and marketing	11,049	9,316	18.6%
Share-based compensation	25,362	4,333	485.3%
Total selling, general and administrative expense	\$ 49,371	\$ 23,093	113.8%

General and administrative. During the three-month period ended June 30, 2009, we experienced an increase of approximately \$1.2 million in general and administrative expenses associated with the operations of our newly constructed facility in North Carolina. In addition, professional fees and corporate travel expenses increased by \$1.4 million during the quarter ended June 30, 2009 compared to the same quarter in 2008.

Sales and marketing. Expenses rose by approximately \$1.5 million for the quarter ended June 30, 2009, compared to the same quarter in 2008, primarily in connection with marketing activities and initiatives relating to Adcirca (tadalafil) tablets and Tyvaso.

Share-based compensation. The increase in share-based compensation expense of approximately \$21.0 million reflects the following: (i) an increase of approximately \$11.6 million in the estimated fair value of a potential year-end stock option grant to our Chief Executive Officer pursuant to the terms of her employment agreement; and (ii) an increase of approximately \$9.4 million in compensation expense associated with STAP awards. This increase resulted principally from the appreciation in the price of our common stock and increases in the number of outstanding STAP awards and the time that these awards have accrued toward vesting at June 30, 2009.

Income taxes. We recognized an income tax benefit of approximately \$3.2 million for the quarter ended June 30, 2009, as a result of the recognition of a pre-tax loss for the quarter. In comparison, the provision for income taxes was \$6.9 million for the three-month period ended June 30, 2008. Income tax expense, or benefit, is based on the estimated annual effective tax rate and is subject to adjustment in subsequent quarterly periods as projections of pre-tax income for the year are revised. The effective tax rate for the three months ended June 30, 2009, was driven in large part by the recognition of a pre-tax loss for the quarter and the decrease in the estimated annual effective tax rate from the quarter ended March 31, 2009. The effective tax rate for the three months ended June 30, 2008, was 37 percent.

Six months ended June 30, 2009 and 2008

The following table sets forth the components of net revenues (dollars in thousands):

	Six Months Ended June 30,		% Change
	2009	2008	
Remodulin	\$ 157,763	\$ 124,500	26.7%
Telemedicine services and products	5,269	4,741	11.1%
Distributor fees	665	1,333	(50.1)%
Other products	13	29	(55.2)%
Total revenues	\$ 163,710	\$ 130,603	25.3%

The growth in revenues for the six months ended June 30, 2009, corresponded in large part to the continued increase in the number of patients being prescribed Remodulin. For the six months ended June 30, 2009 and 2008, approximately 89 percent and 88 percent of net Remodulin revenues were derived from our three U.S.-based distributors.

Total revenues are reported net of estimated government rebates, prompt pay discounts and fees due to our distributors for services. We pay government rebates to state Medicaid agencies that pay for Remodulin. We estimate our liability for these rebates based on the historical level of government rebates invoiced by state Medicaid agencies relative to sales of Remodulin in the United States. Prompt pay discounts are offered on sales of Remodulin if the related invoices are paid in full, generally within 60 days from the date of sale. We estimate our liability for prompt pay discounts based on historical payment patterns. Fees paid to our distributors for services are estimated based on contractual rates for specific services applied to the estimated units of service provided by our distributors for the period.

The table below presents a reconciliation of the liability accounts associated with estimated government rebates, prompt pay discounts and fees to our distributors for services and the net reductions to revenues relating to these items (in thousands):

	Six Months Ended June 30,	
	2009	2008
Liability accounts, at beginning of period	\$ 4,096	\$ 2,878
Additions to liability attributed to sales in:		
Current period	6,476	7,468
Prior period	—	129
Payments or reductions attributed to sales in:		
Current period	(5,217)	(4,382)
Prior period	(1,720)	(2,685)
Liability accounts, at end of period	<u>\$ 3,635</u>	<u>\$ 3,408</u>
Net reductions to revenues	<u>\$ 6,476</u>	<u>\$ 7,597</u>

The table below summarizes research and development expense by significant component (dollars in thousands):

	Six Months Ended June 30,		Percentage Change
	2009	2008	
Program:			
Cardiovascular	\$ 24,523	\$ 26,672	(8.1)%
Other	11,493	6,965	65.0%
Share-based compensation	13,589	6,580	106.5%
Total research and development expense	<u>\$ 49,605</u>	<u>\$ 40,217</u>	<u>23.3%</u>

Cardiovascular. Cardiovascular program expenses for the six-month period ended June 30, 2008, included a \$3.0 million milestone payment to Toray made in connection with the development of beraprost-MR. There were no milestone payments made to Toray during the six months ended June 30, 2009.

Other. The increase in other research and development expenses of approximately \$4.5 million during the six-month period ended June 30, 2009, compared to the same period in 2008, corresponded mainly to an increase in our investigational projects, including those within our glycobiology antiviral agent therapeutic platform.

Share-based compensation Share-based compensation expense increased by \$7.0 million for the six-month period ended June 30, 2009, compared to the six-month period ended June 30, 2008. This increase can be attributed to the following: (i) the increase in the fair value of STAP awards as the result of the appreciation in the price of our common stock; and (ii) increases in the number of outstanding STAP awards, and the time that these awards have accrued toward vesting at June 30, 2009.

The table below summarizes selling, general and administrative expense by major category (dollars in thousands):

	Six Months Ended June 30,		Percentage Change
	2009	2008	
Category:			
General and administrative	\$ 24,343	\$ 18,282	33.2%
Sales and marketing	19,509	16,201	20.4%
Share-based compensation	34,737	7,941	337.4%
Total selling, general and administrative expense	<u>\$ 78,589</u>	<u>\$ 42,424</u>	<u>85.2%</u>

General and administrative. The increase in general and administrative expenses during the six-month period ended June 30, 2009, compared to the same period in 2008, resulted primarily from an increase in professional fees and corporate travel expenses of \$3.5 million, and an increase of approximately \$1.5 million in operating expenses associated with our newly-constructed facility in Research Triangle Park, North Carolina.

Sales and marketing. During the six-month period ended June 30, 2009, expenses increased by approximately \$2.3 million over the same period in 2008 primarily in connection with various marketing activities and initiatives related to Adcirca (tadalafil) tablets and Tyvaso.

Share-based compensation. The increase in share-based compensation expense of approximately \$26.8 million resulted in large part from: (i) an increase of approximately \$14.1 million in the estimated fair value of a potential year-end stock option grant to our Chief Executive Officer pursuant to the terms of her employment agreement; and (ii) an increase of approximately \$12.0 million in compensation expense associated with STAP awards. This increase resulted principally from the appreciation in the price of our common stock and increases in the number of outstanding STAP awards and the time that these awards have accrued toward vesting at June 30, 2009.

Income taxes. Income tax expense was approximately \$3.6 million and \$12.5 million for the six-month periods ended June 30, 2009 and 2008, respectively. Income tax expense is based on the estimated annual effective tax rate and is subject to adjustment in subsequent quarterly periods as projections of pre-tax income for the year are revised. The estimated annual effective tax rates for the six months ended June 30, 2009 and 2008, were approximately 25 percent and 37 percent, respectively. The decrease in the estimated annual effective tax rate for the six months ended June 30, 2009, corresponded to a reduction in projections of pre-tax income for 2009.

Liquidity and Capital Resources

Since Remodulin was initially approved by the FDA in 2002, funding for our operations has been derived principally from related revenues. We believe that our existing revenues and working capital resources will be adequate to fund our operations as demand for Remodulin has grown steadily since 2002 and our customer base remains stable. Furthermore, we believe that our customer base presents minimal credit risk. In addition to Remodulin, Adcirca and Tyvaso, we have several therapies that are in the later stages of development. We believe that our currently approved products and these therapies, if approved, will augment future revenue growth and cash flows. However, any projections of future cash needs and cash flows are inherently subject to uncertainty. To compensate for such uncertainty, we may raise additional cash in the future and believe we have the ability to do so. See *Part II, Item 1A—Risk Factors—We have a history of losses and may not maintain profitability* and *Part II, Item 1A—Risk Factors—We may fail to meet third-party projections for our revenues or profits*.

Operating Cash Flows and Working Capital

Net cash provided by operating activities was \$57.7 million for the six months ended June 30, 2009, compared to approximately \$66.5 million for the same period in 2008. The decrease in cash provided by operating activities resulted principally from the following: (i) a reduction in net income for the six months ended June 30, 2009; (ii) payments of accounts payable and other liabilities as a result of customary variations in our payment processing cycle; and (iii) an increase in accounts receivable due to the routine variations in the timing of sales of Remodulin and their subsequent collections. These reductions to operating cash flows were offset in large part by an increase in non-cash, share-based compensation expense recognized during the six months ended June 30, 2009, as compared to the same period in 2008.

At June 30, 2009, we had working capital of approximately \$211.7 million, compared to approximately \$239.8 million at December 31, 2008. The decrease in working capital as of June 30, 2009, was driven primarily by the \$21.6 million increase in the STAP liability, which is based on the estimated fair value of outstanding STAP awards and included within other current liabilities on the consolidated balance sheets.

Auction-Rate Securities

As of June 30, 2009, we hold approximately \$36.7 million (par value) of illiquid auction-rate securities (ARS). The decline in value of these securities reflects conditions relating to the general collapse of the credit markets. The ARS are collateralized by student loan portfolios that are approximately 91% guaranteed by the federal government and maintain a credit rating of AAA. Historically, these securities provided liquidity to investors through their interest rate reset feature -- i.e., interest rates on these securities are reset through a bidding process (or auction) at frequent, pre-determined intervals (typically every 7 to 28 days). At each reset date, investors can choose to either maintain their holdings or liquidate them at par value. Since February 2008, auctions related to our ARS have failed, rendering these securities illiquid.

To mitigate the risks associated with these securities, we entered into an Auction Rate Securities Rights Offer (Rights Offer) during the fourth quarter of 2008 with the investment firm that maintains our ARS account. Pursuant to the Rights Offer, we can sell our ARS to the investment firm for a price equal to the par value of these securities at any time between June 30, 2010, and July 2, 2012. In addition, to help meet any immediate liquidity needs, the Rights Offer permits us to borrow up to the par value of the ARS. The Rights Offer provides us with additional flexibility to recover the full cost of our investment prior to the maturity of these securities. However, the Rights Offer exposes us to counterparty credit risk. Based on our anticipated cash requirements and cash flows, we do not believe that the risks associated with the ARS will materially impact our ability to meet our obligations.

Construction Projects

In February 2009, we completed the construction of our facility in Research Triangle Park, North Carolina (RTP Facility). The RTP Facility is approximately 200,000 square feet and consists of a manufacturing operation and office space. The manufacturing operation will be used primarily for the production of oral treprostinil. In addition, it is expected that the RTP Facility will support the production and distribution of other drug candidates that we are developing. Our clinical development, regulatory and sales and marketing personnel occupy the facility's office space.

In December 2007, we began constructing a combination office and laboratory facility (the Phase II Facility) that will attach to our Phase I Laboratory. We anticipate that it will cost \$100.0 million to complete construction of this facility. In May 2009, we amended the terms of our November 2008 guaranteed maximum price construction management agreement with the Whiting-Turner Contracting Company (Whiting-Turner) for the construction of the Phase II Facility. The May 2009 amendment converted the guaranteed maximum price into a lump sum and increased our total obligation from approximately \$61.3 million to \$66.0 million, as a result of several change-orders previously agreed-upon with Whiting-Turner. We will not be obligated to Whiting-Turner for costs

that exceed the lump-sum value of the contract unless such costs result from agreed-upon change orders that extend beyond the original scope of work. Projections of costs to complete this facility include various expenditures that we expect to incur that are outside the contract's scope of work.

During the three- and six-month periods ended June 30, 2009, we spent approximately \$17.5 million and \$27.0 million, respectively, on the construction of the Phase II Facility. As of June 30, 2009, inception-to-date expenditures approached \$146.0 million on the construction of the RTP and Phase II Facilities. We expect to fund the construction of the Phase II Facility using existing cash and cash flows generated by our operations.

Share Tracking Awards Plan

Awards granted under the STAP (Awards) entitle participants to receive an amount in cash equal to the appreciation in our common stock, which is calculated as the positive difference between the closing price of our common stock on the date of exercise and the date of grant. Accordingly, the STAP will likely require substantial future outlays of cash as the number of vested Awards increases over time and participants exercise their Awards. Our current and projected five-year operating budgets incorporate anticipated cash requirements of the STAP, and we believe future cash flows will be sufficient to accommodate our obligations under the STAP.

Convertible Senior Notes

On October 30, 2006, we issued at par value \$250.0 million of 0.50% Convertible Senior Notes due October 2011 (Convertible Senior Notes). We pay interest on the Convertible Senior Notes semi-annually on April 15 and October 15 of each year. The Convertible Senior Notes are unsecured, unsubordinated obligations that rank equally with all of our other unsecured and unsubordinated indebtedness.

Conversion can occur: (i) anytime after July 15, 2011; (ii) during any calendar quarter that follows a calendar quarter in which the price of our common stock exceeded 120% of the initial conversion price for at least 20 days during the 30 consecutive trading-day period ending on the last trading day of the quarter; (iii) during the ten consecutive trading-day period following any five consecutive trading-day period in which the trading price of the Convertible Senior Notes was less than 95% of the closing price of our common stock multiplied by the then current number of shares underlying the Convertible Senior Notes; (iv) upon specified distributions to our shareholders; (v) in connection with corporate transactions; or (vi) in the event that our common stock ceases to be listed on the NASDAQ Global Select Market (NASDAQ) and is not listed for trading on another U.S. national or regional securities exchange.

Upon conversion, a holder of our Convertible Senior Notes will receive: (i) cash equal to the lesser of the principal amount of the note or the conversion value (equal to the number of shares underlying the Convertible Senior Notes multiplied by the then current conversion price per share); and (ii) to the extent the conversion value exceeds the principal amount of the Convertible Senior Notes, shares of our common stock. In the event of a change in control, as defined in the indenture under which the Convertible Senior Notes have been issued, holders can require us to purchase from them all or a portion of their Convertible Senior Notes for 100% of the principal value plus any accrued and unpaid interest.

Because the Convertible Senior Notes include contingent conversion provisions, investors may be able to convert their Convertible Senior Notes prior to October 2011. However, it is our expectation, based on our understanding of the historical behavior of holders of convertible notes with terms similar to ours, that most, if not all of our outstanding Convertible Senior Notes will be held until they mature in October 2011.

Lease Obligation

We lease our Phase I Laboratory pursuant to a synthetic lease arrangement (Lease) entered into in June 2004 with Wachovia Development Corporation and its affiliates (Wachovia). Under the Lease, Wachovia funded \$32.0 million toward the construction of the Phase I Laboratory on land that we own. Subsequent to the completion of construction in May 2006, Wachovia leased the Phase I Laboratory to us. Monthly rent is equal to the 30-day London Interbank Offered Rate (LIBOR) plus 55 basis points (0.86% as of June 30, 2009) applied to the amount Wachovia funded toward construction. The base term of the Lease ends in May 2011 (Base Term). Upon the end of the Base Term, we will have the right to exercise one of the following options under the Lease: (i) renew the Lease for an additional five-year term (subject to the approval of both parties); (ii) purchase the Phase I Laboratory from Wachovia for approximately \$32.0 million; or (iii) sell the Phase I Laboratory and repay Wachovia's construction costs with the proceeds from the sale. If the sale proceeds are insufficient to repay Wachovia's construction costs, we must fund the shortfall up to a maximum residual value guarantee of approximately \$27.5 million. From the inception of the Lease through August 2008, we accounted for the Lease as an operating lease.

In December 2007, we began constructing the Phase II Facility with funds generated from our operations. As of September 30, 2008, we received Wachovia's acknowledgement of our plan to make structural modifications to the Phase I Laboratory in order to connect it to the Phase II Facility. As a result, we could no longer consider the Phase I Laboratory a standalone structure, which was required to maintain off-balance sheet accounting for the Lease. Consequently, as of September 30, 2008, we were considered the owners of the Phase I Laboratory for accounting purposes and began accounting for the Lease as a financing obligation. Accordingly, we capitalized \$29.0 million, the estimated fair value of the Phase I Laboratory, and recognized a corresponding lease obligation on our consolidated balance sheet. We are accreting the lease obligation, \$32.0 million, the purchase price of the Phase I Laboratory, through the recognition of periodic interest charges using the effective interest method. The accretion period will run through the end of the Base Term. In addition, we are depreciating the Phase I Laboratory over the estimated useful lives of its various components.

Using the 30-day LIBOR as of June 30, 2009, plus 55 basis points, our estimated annual rent under the Lease would be \$274,000. Approximately \$41.1 million of our marketable investments at June 30, 2009, have been pledged as collateral for the Lease and are included within restricted marketable investments and cash on our consolidated balance sheet.

Summary of Critical Accounting Policies

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (GAAP) requires our management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments. Our estimates and judgments are based on historical and anticipated results and trends and on other assumptions that we believe are reasonable under the circumstances, including assumptions regarding future events. By their nature, our estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ. We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity within *Part II, Item 7—Management's Discussion and Analysis of Financial Condition and Results of Operations* in our Annual Report on Form 10-K for the year ended December 31, 2008. There have been no material changes to our critical accounting policies and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2008, except for our adoption of Financial Accounting Standards Board (FASB) Staff Position No. APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement)* (FSP APB 14-1), on January 1, 2009 (see Note 9—*Adoption of FSP APB 14-1*, to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further discussion).

Recent Accounting Developments

In June 2009, the FASB issued Statement of Financial Accounting Standard (SFAS) No. 168, *The FASB Accounting Standards Codification™ and the Hierarchy of Generally Accepted Accounting Principles — a replacement of FASB Statement No. 162* (SFAS 168). SFAS 168 replaces SFAS 162, *The Hierarchy of Generally Accepted Accounting Principles* and establishes the *FASB Accounting Standards Codification™* (FASC), as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. All guidance within the FASC carries an equal level of authority. In addition, SEC rules and interpretive guidance are considered authoritative guidance for SEC registrants. Neither the issuance of this standard nor the launch of the FASC on July 1, 2009, was intended to alter existing GAAP. SFAS 168 becomes effective for interim and annual financial reporting periods ending after September 15, 2009. We are assessing what impact, if any, the adoption of this standard may have on our consolidated financial statements, and expect any references to legacy standards contained in our consolidated financial statements to be revised to reflect updated referencing under the FASC.

In June 2009, the FASB issued SFAS No. 167, *Amendments to FASB Interpretation No. 46(R)* (SFAS 167). SFAS 167 requires a qualitative approach for determining the primary beneficiary of a variable interest entity and replaces the quantitative evaluation set forth under FASB Interpretation No. 46 (revised December 2003), *Consolidation of Variable Interest Entities* (FIN 46R). Additionally, under SFAS 167, primary beneficiary designation will need to be assessed on an ongoing basis. Among other amendments to FIN 46R, SFAS 167 eliminates the qualifying special-purpose entity scope exception and requires enhanced disclosures about an entity's involvement in variable interest entities. SFAS 167 is effective for the first annual period beginning after November 15, 2009, and interim periods within that first annual period. We are assessing what impact, if any, adoption of this standard will have on our consolidated financial statements.

In May 2008, the FASB issued SFAS No. 165, *Subsequent Events* (SFAS 165), to address the accounting and disclosure requirements relating to subsequent events. SFAS 165 requires issuers to evaluate events that occur after the balance sheet date through the date the financial statements are issued or available to be issued for potential recognition and/or disclosure. In addition, SFAS 165 clarifies when financial statements are available to be issued and requires disclosure of the date through which financial

statement issuers evaluated subsequent events. SFAS 165 is effective for interim and annual periods ending after June 15, 2009. The adoption of SFAS 165 had no impact on our consolidated financial statements.

In April 2009, the FASB issued FASB Staff Position (FSP) FAS No. 115-2 and FAS 124-2, *Recognition and Presentation of Other-Than-Temporary Impairments* (FSP FAS 115-2/FAS 124-2), to modify the existing impairment model with respect to debt securities falling within its scope. Under FSP FAS 115-2/FAS 124-2, an other-than-temporary impairment (OTTI) will have occurred when either: (i) an entity has the intent to sell an impaired security; (ii) it is more likely than not that an entity will be required to sell an impaired security prior to its anticipated recovery in value; or (iii) an entity does not expect to recover the entire cost basis of an impaired security. In addition, FSP FAS 115-2/FAS 124-2 modifies the manner in which an OTTI is measured and presented on the statement of operations and requires expanded disclosures. FSP FAS 115-2/FAS 124-2 is effective for interim and annual reporting periods ending after June 15, 2009. Adoption of FSP FAS 115-2/FAS 124-2 did not have a material impact on our consolidated financial statements, but resulted in additional disclosure requirements about our investments—see Note 5 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further discussion.

In April 2009, the FASB issued FSP No. FAS 157-4, *Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly*, (FSP FAS 157-4). FSP FAS 157-4 provides guidance in determining: (i) whether there has been a significant decline in market activity for a particular asset or liability; (ii) whether transactions in a market are orderly or not; and (iii) when, and to what extent, other valuation approaches should be considered in estimating fair value. In addition, FSP FAS 157-4 amends SFAS No. 157, *Fair Value Measurements*, to require disclosure of the inputs and valuation techniques underlying fair value measurements and any changes in valuation techniques and related inputs for interim and annual reporting periods. FSP FAS 157-4 is effective for financial reporting periods ending after June 15, 2009. Adoption of FSP FAS 157-4 did not result in a material change to valuation methods used to estimate the fair value of our Level 3 assets; however, adoption of this staff position resulted in additional interim disclosures that have been included in Note 4 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments*, (FSP FAS 107-1/APB 28-1). FSP FAS 107-1/APB 28-1 amends SFAS No. 107, *Disclosures about Fair Value of Financial Instruments* (SFAS 107), to require fair value disclosures about financial instruments set forth under SFAS 107 for interim and annual reporting periods. Adoption of FSP No. FAS 107-1 and APB 28-1 resulted in additional interim disclosures about fair value that have been included in Note 4 — *Fair Value of Financial Instruments* to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of June 30, 2009, we held investments of approximately \$36.7 million (par value) in ARS. We are exposed to market risk related to the ARS as a result of the general collapse of the credit markets and the continued uncertainty surrounding the financial markets. The ARS maintain an AAA credit rating and are backed by student loan portfolios that are approximately 91% guaranteed by the federal government. However, since February 2008, auctions for the ARS have failed, rendering these securities illiquid. Consequently, the fair value of the ARS has experienced a significant decline in value. As of June 30, 2009, the estimated fair value of these securities was approximately \$28.0 million. Because we classify the ARS as trading securities, all future changes in fair value will be recognized within earnings until the securities are liquidated or otherwise disposed. Furthermore, there can be no assurances that the ARS will ever fully recover their value.

To mitigate market-related risks associated with our investment, we entered into the Rights Offer, under which we have a put option that gives us the ability to require the investment firm (the counterparty to the Rights Offer) to repurchase the ARS at a price equal to their par value anytime between June 30, 2010 and July 2, 2012 (Put Option). The Put Option has been recognized at fair value as a financial asset on our consolidated balance sheet and subsequent changes in its fair value will be recognized within earnings. We expect the future price movements relating to the ARS and the Put Option to largely offset one another -- i.e., as the value of the ARS decreases, we would expect the rights associated with the Put Option to increase in value. However, the Rights Offer and the related Put Option still expose us to counterparty credit risk.

As of June 30, 2009, we have invested approximately \$210.7 million in debt securities issued by corporations and federally-sponsored agencies. The market value of these investments varies inversely with changes in current market interest rates. In general, as rates increase, the market value of a debt investment would be expected to decrease. Similarly, as rates decrease, the market value of a debt investment would be expected to increase. To address market risk, we invest in debt securities that mature within two years and hold these investments to maturity so that they can be redeemed at their stated or face value. At June 30, 2009, our investments in debt securities issued by corporations and federally-sponsored agencies had a weighted average stated interest rate of approximately 2.2%. These investments mature at various times through 2011 and are callable annually.

There has been a prolonged period of significant deterioration and instability in the financial markets that has persisted into 2009. This period of extraordinary disruption and readjustment in the financial markets exposes us to additional investment risk. The value and liquidity of the securities in which we invest could deteriorate rapidly and the issuers of such securities could be subject to credit rating downgrades. In light of the current market conditions and the additional risks to which we may be exposed, we actively monitor market conditions and developments specific to the securities and security classes in which we invest. We believe that we take a conservative approach to investing our funds in that we invest exclusively in highly rated securities with relatively short maturities. Furthermore, we do not invest in the types of securities that expose us to undue risk. While we believe we take prudent measures to mitigate investment related risks, such risks cannot be fully eliminated, as circumstances can occur that are beyond our control.

Item 4. CONTROLS AND PROCEDURES

Based on their evaluation, as of June 30, 2009, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) are effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, summarized, processed and reported within the time periods specified in the SEC's rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, such internal control over financial reporting.

Part II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

On May 7, 2009, purported shareholder Jeffrey Benison IRA filed a derivative complaint in the Court of Chancery for the State of Delaware against each of our directors other than our newly-appointed director, Richard Giltner, and us as nominal defendant. The complaint, which the plaintiff purports to bring on our behalf, alleges among other things that the named director defendants breached their fiduciary duty of loyalty and committed waste in connection with the adoption of the United Therapeutics Corporation Share Tracking Awards Plan (STAP) in June 2008 and the late 2008 modification of awards granted under the STAP and repricing of certain stock options granted under our Amended and Restated Equity Incentive Plan. We disclosed all of these actions in our filings with the Securities and Exchange Commission, including our current reports on Form 8-K, filed on June 6, 2008, November 26, 2008 and December 31, 2008, our tender offer statement on Schedule TO, filed on November 26, 2008, and amendments thereto filed on December 5 and 31, 2008, our annual report on Form 10-K, filed on February 26, 2009, our definitive proxy statement on Schedule 14A, filed on April 29, 2009 and our quarterly report on Form 10-Q, filed on May 1, 2009. The plaintiff is seeking unspecified monetary damages purportedly for United Therapeutics Corporation, as well as attorneys' fees and costs and injunctive relief, including revocation and/or revision of the STAP. We believe the plaintiff's allegations are without merit and intend to defend against these claims vigorously. Furthermore, we have been advised that the individual director defendants also intend to defend against these claims vigorously.

On July 28, 2009, another purported shareholder, the Retirement Board of Allegheny County, filed a complaint in the Court of Chancery for the State of Delaware against us. The lawsuit seeks an order allowing the plaintiff to inspect our records relating principally to the same issues addressed in the complaint filed by Jeffrey Benison IRA, as well as attorneys' fees and costs.

From time to time, we may be involved in other lawsuits and proceedings incidental to the conduct of our business. We are not a party to any other lawsuit or proceeding that, in the opinion of our management, is likely to have a material adverse effect on our financial position or results of operations.

Item 1A. RISK FACTORS

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act) and the Private Securities Litigation Reform Act of 1995 which are based on our beliefs and expectations as to future outcomes. These statements include, among others, statements relating to the following:

- Expectations of revenues, profitability, and cash flows;
- The sufficiency of current and future working capital;
- The expectation that our 0.50% Convertible Senior Notes due October 2011 (Convertible Senior Notes) will be held to maturity;
- The ability to obtain financing or raise capital in the future;
- The expectation of liquidating our investment holdings without significant losses;
- The value of our common stock;
- The timing and outcome of clinical studies and regulatory filings;
- The pace and timing of enrollment in our clinical trials;
- The expectation and timing of regulatory approvals for drug candidates under development and the timing of related sales;
- The achievement and/or maintenance of both domestic and international regulatory approvals;
- The outcome of potential future regulatory actions, including audits and inspections, from the United States Food and Drug Administration (FDA) and international regulatory agencies;
- The existence and activities of competitors;

- The pricing of Remodulin[®] (treprostinil sodium) Injection (Remodulin);
- The pricing of Adcirca[™] (tadalafil) tablets (Adcirca);
- The pricing of Tyvaso[™] (treprostinil) Inhalation Solution (Tyvaso);
- The expected volume and timing of Remodulin, Adcirca and Tyvaso sales;
- The dosing and rate of patient consumption of Remodulin, Adcirca and Tyvaso;
- The impact of competing therapies, including generic products, on Remodulin, Adcirca and Tyvaso sales;
- The expectation that we will be able to maintain adequate inventories of Remodulin and Tyvaso at all times;
- The adequacy of our intellectual property protections and expiration dates on our patents;
- The ability of third parties to market, distribute and sell our products;
- The projected timing and costs relating to our construction projects;
- The potential effects of the Auction Rate Securities Rights Offer and our expectations regarding the right to borrow thereunder;
- The expected timing of payments to third parties under license agreements;
- The outcome of any litigation in which we are or become involved;
- The expected impact of new accounting standards;
- The expectation that our business tax credit carryforwards will be fully utilized;
- Any statements preceded by, followed by or that include any form of the words “believe,” “seek,” “expect,” “predict,” “anticipate,” “forecast,” “project,” “intend,” “estimate,” “should,” “could,” “may,” “will,” or similar expressions; and
- Other statements contained or incorporated by reference in this Quarterly Report on Form 10-Q that are not historical facts.

The statements identified as forward-looking statements may exist in the section entitled *Part I, Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations* or elsewhere in this Quarterly Report on Form 10-Q. These statements are subject to risks and uncertainties and our actual results may differ materially from anticipated results. Factors that may cause such differences include, but are not limited to, those discussed below. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Risks Related to Our Business

We have a history of losses and may not maintain profitability.

We have experienced financial reporting periods in which we incurred net losses. For the year ended December 31, 2008, we recognized a net loss of approximately \$49.3 million as we incurred a fourth quarter charge to research and development of \$150.0 million in connection with our license of certain rights to commercialize tadalafil from Eli Lilly & Company (Lilly). While we believe we formulate our annual operating budgets with reasonable assumptions and targets, there may be factors that are outside of our control that could affect our profitability and cause uneven quarterly and/or annual operating results.

We rely heavily on sales of Remodulin to produce revenues.

During the six months ended June 30, 2009, net Remodulin sales accounted for approximately 96 percent of our total revenues. A wide variety of events, many of which are described in other risk factors below, could cause net Remodulin sales to

decline. For example, if regulatory approvals for Remodulin were withdrawn, we would be unable to sell our product and our business could be jeopardized. In the event that GlaxoSmithKline PLC (Glaxo) terminates its assignment agreement or Pfizer, Inc. (Pfizer) terminates its license agreement, we would have no further rights to utilize assigned patents or trade secrets to develop and commercialize Remodulin. Any substantial change in the dosing pattern of patients using Remodulin, due to combination therapy, side effects, death or any other reason, could decrease related revenues. In addition, we rely on third parties to produce, market, distribute and sell Remodulin. The inability of any one of these third parties to perform these functions, or the failure of these parties to perform successfully, could negatively affect our revenues. Because we are very dependent on sales of Remodulin, any reduction in Remodulin sales would cause our results of operations to suffer.

Most of our pharmaceutical products are in clinical development and may never generate profits.

Most of our pharmaceutical products are at various stages of clinical development. Many of these products may not become commercially available for a number of years, if at all. We might not maintain or obtain regulatory approvals in the U.S. and/or major markets worldwide for our pharmaceutical products and may not be able to sell our pharmaceutical products commercially. Even if we are able to sell our products, we may not be profitable or may not be able to sustain any profitability we achieve.

We may not compete successfully with established and newly-developed drugs, products and the companies that develop and market them.

We compete with established drug companies for, among other things, funding, licenses, expertise, personnel, clinical trial patients, and third-party collaborators. We also compete with these companies for market share. Most of these competitors have substantially greater financial, marketing, sales, distribution and technical resources than we do. These competitors also possess more experience in areas such as research and development, clinical trials, sales and marketing and regulatory matters than we do.

There are existing treatments that compete with our products, especially in the field of PAH. For the treatment of PAH, we compete with several approved products in the United States and worldwide, including the following: Flolan[®], Ventavis[®], Tracleer[®], Revatio[®], Letairis[™], Thelin[®] and several generic epoprostenol formulations. Patients and doctors may perceive these competing products as safer, more effective, more convenient and/or less expensive than Remodulin, Adcirca or Tyvaso. Alternatively, doctors may reduce the prescribed doses of Remodulin, Adcirca or Tyvaso if they prescribe them as combination therapy or in combination with our competitors' products. In addition, certain competing products are less invasive than Remodulin and the use of these products may delay or prevent initiation of Remodulin therapy. Any of these circumstances may stunt our sales growth, or cause our revenues to decline.

As a result of merger activity, Actelion Ltd (Actelion), Gilead Sciences, Inc. and Pfizer presently control the majority of non-generic approved therapies for PAH in the United States. Furthermore, Actelion controls one of the two recently approved generic formulations of epoprostenol. In addition to reducing the number of competitors through merger activity, each of these companies has achieved considerable influence over prescribers through the sales and marketing of their respective therapies and through market dominance in this therapeutic area. The future commercialization of additional generic forms of PAH therapies could exert downward pressure on the pricing of our products.

Discoveries or development of new products or technologies by others may make our products obsolete or less useful.

Companies may discover or introduce new products that render all or some of our technologies and products obsolete or noncompetitive. Remodulin, Adcirca and Tyvaso may have to compete with numerous investigational products currently in development. In addition, alternative approaches to treating chronic diseases, such as gene therapy, may make our products obsolete or noncompetitive. Other investigational therapies for PAH could be used in combination with, or as a substitute for Remodulin, Adcirca or Tyvaso. If this occurs, doctors may reduce or discontinue the use of Remodulin, Adcirca or Tyvaso for their patients.

If third-party payers do not reimburse patients for our drug products or if third-party payers reduce or limit reimbursements, our sales will suffer.

Third-party payers such as Medicare, Medicaid and private insurance companies agree to reimburse patients for the costs of our pharmaceutical products. Accordingly, our commercial success is tied to such third-party payers. These third-party payers frequently challenge the pricing of new and expensive drugs and we believe that the products we are currently developing will be expensive if they are approved for commercialization. Consequently, it may be difficult for our distributors to obtain reimbursement from third-party payers. Alternatively, third-party payers may reduce the amount of reimbursement for Remodulin, Adcirca or Tyvaso based on changes in pricing of other therapies for PAH, including generic formulations of other approved therapies. If third-party payers do not approve a product of ours for reimbursement or limit the amount of reimbursement, patients could opt for a competing product that is approved for reimbursement.

Presently, most third-party payers, including Medicare and Medicaid, reimburse patients for the cost of Remodulin therapy, which is expensive. The Medicare Modernization Act (MMA) requires that we negotiate a new price for Remodulin with the Centers for Medicare and Medicaid Services. As a result of the staggered implementation of the MMA, Remodulin has not yet been subject to its pricing provisions; however, future reimbursements could be subject to reduction. Furthermore, to the extent that private insurers or managed care programs follow any reduced Medicaid and Medicare coverage and payment developments, the negative impact on our business would be compounded. Further legislative developments related to health-care reform at the federal and state level appear likely and such legislation could adversely impact our business.

We rely in part on third parties to perform activities that are critical to our business . Our ability to generate commercial sales or conduct clinical trials could suffer if our third-party suppliers and service providers fail to perform.

Frequently, we involve third parties to assist us in conducting clinical studies, obtaining regulatory approvals, marketing and distributing our products as we do not possess the capacity to perform all of these functions internally. Accordingly, the success of these third parties in performing their contracted obligations is critical to our operations. Furthermore, we may not locate acceptable contractors or enter into favorable agreements with them.

We manufacture treprostinil with raw materials and advanced intermediate compounds supplied by vendors. The inability of our vendors to supply these raw materials and advanced intermediate compounds in the quantities we require could delay the manufacture of treprostinil for commercial use and for use in clinical trials.

We rely on third parties to formulate our treprostinil-based products. Baxter International Inc. (Baxter) formulates Remodulin for us. We are also evaluating alternative supply arrangements, including other third-party production arrangements and the formulation of Remodulin in our combination office and laboratory facility that we are currently constructing in Silver Spring, Maryland. In addition, during the second half of 2009, we plan to increase our supply of formulated Remodulin to cover three years of expected demand. If we are unable to implement these alternatives satisfactorily, we may not have sufficient inventory levels of Remodulin to meet future demand.

Catalent Pharma Solutions, Inc. (Catalent) conducts stability studies on Remodulin and Tyvaso for us, formulates Tyvaso and oral treprostinil and analyzes other products that we are developing. Beginning in the second half of 2009, we plan to formulate oral treprostinil at our new manufacturing facility in Research Triangle Park, North Carolina. This will be our initial attempt at formulating oral treprostinil without the use of a third party; therefore, we may encounter unforeseen obstacles.

We engage NEBU-TEC International Med Products Eike Kern GmbH (NEBU-TEC) to manufacture the Tyvaso Inhalation System used with Tyvaso. NEBU-TEC is responsible for managing the manufacturing process of the Tyvaso Inhalation System in accordance with all applicable regulatory requirements. Any regulatory compliance problems encountered by NEBU-TEC relative to the manufacture of this device could adversely affect regulatory approvals of Tyvaso. Consequently, this could impede the projected growth in our business.

We rely on Accredo Therapeutics, Inc., CuraScript, Inc., and CVS Caremark to market, distribute and sell Remodulin in the United States. These distributors are also responsible for negotiating patient reimbursements from third-party payers for the cost of Remodulin therapy, which is expensive. If our distributors do not recognize acceptable profit margins on such arrangements, they may discontinue the sale of related products. Furthermore, if our domestic and international distributors devote fewer resources to selling Remodulin or are unsuccessful in their sales efforts, our revenues will suffer.

Pursuant to certain rights we licensed from Lilly in 2008 regarding the commercialization of Adcirca, Lilly will manufacture and supply Adcirca for us and we will use Lilly's wholesaler network to distribute Adcirca in the United States and Puerto Rico. If Lilly is unable to manufacture or supply Adcirca or its distribution network is disrupted, it could delay, disrupt or prevent us from selling Adcirca.

Although most of our current suppliers and service providers could be replaced, a change in suppliers and/or service providers could interrupt the distribution of Remodulin and our other products and services, and impede the progress of our clinical trials, commercial launch plans and related revenues.

Our manufacturing strategy presents the following risks:

- We and the manufacturers and formulators of our products are subject to the FDA's current Good Manufacturing Practices in the United States and similar stringent regulatory standards internationally. Although we can control compliance issues with respect to our internal synthesis and manufacturing processes, we do not have control over regulatory compliance by our third-party manufacturers;
- Even if we and the manufacturers and formulators of our products were to comply with domestic and international drug manufacturing regulations, the sterility and quality of the products being manufactured and formulated could be deficient. If this were to occur, such products would not be available for sale or use;
- If we have to replace a third-party manufacturer or formulator or our own manufacturing or formulation operations, the FDA and its international counterparts would require new testing and compliance inspections. Furthermore, a new manufacturer or formulator, would have to be educated in the processes necessary to manufacture and commercially validate our product, as manufacturing our treprostinil-based products is complex;
- We may be unable to contract with needed manufacturers and formulators on satisfactory terms or at all; and
- The supply of materials and components necessary to manufacture and package Remodulin and our other products may become scarce or interrupted. Disruptions to the supply of these materials could delay the manufacture and subsequent sale of such products. Any products manufactured with substituted materials or components would be subject to approval from the FDA and international regulatory agencies before they could be sold. The timing of any such regulatory approval is difficult to predict.

Any of these factors could delay clinical trials or commercialization of our products, entail higher costs, and result in the inability to sell our products effectively.

Our operations must comply with extensive FDA and comparable international regulations. Failure to obtain approvals on a timely basis or to achieve continued compliance could delay, disrupt or prevent the commercialization of our products.

The products we develop must be approved for marketing and sale by regulatory agencies and, once approved, are subject to extensive regulation by the FDA and comparable regulatory agencies outside the United States. The process of obtaining and maintaining regulatory approvals for new drugs is lengthy, expensive and uncertain. The manufacture, distribution, advertising and marketing of these products are also subject to extensive regulation. Any future product approvals we receive could impose significant restrictions on the use or marketing of the product. Potential products may fail to receive marketing approval on a timely basis, or at all. If granted, product approvals can be withdrawn for failure to comply with regulatory requirements -- e.g., a failure to comply with the FDA's post-marketing requirement and post-marketing conditions for Tyvaso -- or upon the occurrence of adverse events subsequent to commercial introduction. We are subject to similar oversight and regulation governing how we manufacture and sell approved products.

Discovery of previously unknown problems with our marketed products or problems with our manufacturing, regulatory, compliance, promotional or selling activities could result in regulatory restrictions on our products, including withdrawal of the products from the market. If we fail to comply with applicable regulatory requirements, we could be subject to penalties that may consist of fines, suspension of regulatory approvals, product recalls, seizure of products and/or criminal prosecution.

Reports of side effects, such as sepsis, associated with intravenous Remodulin could cause physicians and patients to avoid or discontinue use of Remodulin in favor of alternative treatments.

Sepsis is a serious and potentially life-threatening infection of the bloodstream caused by a wide variety of bacteria. Intravenous prostacyclins are infused continuously through a catheter placed in a large vein in the patient's chest. Sepsis is an expected consequence of this type of delivery. As a result, sepsis is included as a risk in both the Remodulin and Flolan package inserts. Although a discussion of the risk of sepsis is currently included on the Remodulin label, and the occurrence of sepsis is familiar to physicians who prescribe intravenously administered therapies, concerns about bloodstream infections may adversely affect a physician's prescribing practice of Remodulin.

If our products fail in clinical trials, we will be unable to obtain or maintain FDA and international regulatory approvals and will be unable to sell those products.

In order to sell our pharmaceutical products, we must receive regulatory approvals from the FDA and international regulatory agencies such as the European Medicines Agency (EMA). To obtain those approvals, we must conduct clinical trials demonstrating that our products, including their delivery mechanisms, are safe and effective. In the past, several of our product candidates failed or were discontinued at various stages in the development process. In addition, we may need to amend ongoing trials or the FDA and/or international regulatory agencies may require us to perform additional trials beyond those we planned. Such occurrences could result in significant delays and additional costs and related clinical trials may be unsuccessful. In November 2008, we reported that our FREEDOM-C clinical trial of oral treprostinil did not achieve statistical significance for its primary endpoint. Because we have decided to amend the protocol for our current FREEDOM-M clinical trial and conduct a new clinical trial, FREEDOM-C², we expect delays in completing our clinical trials for oral treprostinil and do not anticipate filing a New Drug Application (NDA) prior to 2012.

The length of time that it takes for us to complete clinical trials and obtain regulatory approval for marketing varies by product, product use and country. Furthermore, we cannot predict with certainty the length of time it will take to complete necessary clinical trials or obtain regulatory approval of our future products.

Our clinical trials may be discontinued, delayed, or disqualified for various reasons. These reasons include:

- The drug is ineffective, or physicians believe that the drug is ineffective;
- Patients do not enroll in our studies at the rate we expect;
- Ongoing or new clinical trials conducted by drug companies in addition to our own clinical trials may reduce the number of patients available for our trials;
- Patients experience severe side effects during treatment;
- Other investigational or approved therapies are viewed as more effective or convenient by physicians or patients;
- Our clinical trial sites do not adhere to the trial's protocol;
- Our trials do not comply with applicable regulations or guidelines;
- We do not pass inspections by regulatory agencies;
- Patients die during our trials because of an adverse event related to the trial drug, their disease is too advanced, or they experience medical problems unrelated to the drug being studied;
- Drug supplies are unavailable or unsuitable for use in our studies; and
- The results of preclinical testing cause delays in our trials.

In addition, the FDA and its international equivalents have substantial discretion over the approval process for pharmaceutical products. As such, these regulatory agencies may not agree that we have demonstrated the requisite level of product safety and efficacy.

Our corporate compliance program cannot guarantee that we comply with all potentially applicable federal, state and international regulations.

The development, manufacture, distribution, pricing, sales, marketing, and reimbursement of our products, together with our general operations, are subject to extensive federal, state, local and international regulations. These regulations are subject to frequent revisions that often introduce more stringent requirements. While we believe we have developed and instituted adequate corporate compliance programs, we cannot ensure that we will always be in compliance with these regulations. If we fail to comply with any of these regulations, we could be subject to a range of penalties including, but not limited to: the termination of clinical trials, the failure to approve a product candidate, restrictions on our products or manufacturing processes, withdrawal of our products from the market, significant fines, exclusion from government healthcare programs, and other sanctions or litigation.

If the licenses, assignments and alliance agreements we depend on are breached or terminated, we could lose our right to develop and sell products covered by such agreements.

Our business depends upon the acquisition, assignment and license of drugs and other products that have been discovered and initially developed by others, including Remodulin, Adcirca, Tyvaso and many other products in our key therapeutic platforms. Under our product license agreements, we receive certain rights to existing intellectual property owned by third parties subject to the terms of each license agreement. Our assignment agreements transfer all right, title and interest in the intellectual property to us, subject to the terms of each agreement. In addition, we may be required to obtain licenses to other third-party technologies to commercialize our early-stage products. This dependence on technology developed by others contains the following risks:

- We may be unable to obtain future licenses or assignment agreements at a reasonable cost or at all;
- If any of our licenses or assignment agreements are terminated, we will lose our rights to develop and market related products;
- Our license and assignment agreements generally provide the licensor or assignor the right to terminate these arrangements in the event we breach such agreements -- e.g., we fail to pay royalties and other fees timely; and
- If a licensor or assignor fails to maintain the intellectual property licensed or assigned to us as required by most of our license and assignment agreements, we may lose our rights to develop and market some or all of our products. In addition, we may be forced to incur substantial costs to maintain the intellectual property ourselves or force the licensor or assignor to do so.

Certain license and assignment agreements may restrict our ability to develop related products in certain countries and/or for particular diseases and may impose other restrictions on our freedom to develop and market our products.

When we license or are assigned drugs and other products that have been discovered and initially developed by third parties, our rights are frequently limited. For instance, our rights to market Adcirca are geographically limited to the United States and Puerto Rico; however, we would have an opportunity to negotiate with Lilly for the rights to market Adcirca in other territories in the event that Lilly decides not to market Adcirca in a particular country. Furthermore, we cannot undertake any additional investigatory work with respect to Adcirca in other indications of pulmonary hypertension without Lilly's prior approval. Lilly also has authority over all regulatory activities, the right to determine the retail price for Adcirca and the wholesale price at which we will purchase Adcirca from Lilly.

Provisions in our license and assignment agreements may impose other restrictions that affect our ability to develop and market related products. For example, Glaxo retained an exclusive option and right of first refusal to negotiate a license agreement with us if we decide to license any aspect of the commercialization of Remodulin anywhere in the world. Similarly, our amended license agreement with Toray Industries, Inc. (Toray) includes a conditional non-compete clause that grants Toray the right to be our exclusive provider of beraprost-MR. Moreover, we must also meet certain minimum annual sales to maintain our exclusive rights to beraprost-MR.

If our or our suppliers' patents or other intellectual property protections are inadequate, our revenues and profits could suffer or our competitors could force our products out of the market.

The period under which our commercial and developmental therapies are protected by our patent rights is limited. Our U.S. patent for the method of treating PAH with Remodulin will expire in October 2014 (it has already received the maximum five-year extension). Patents covering methods of making Remodulin in the U.S. and the EU expire in October 2017. The patent for Adcirca for the treatment of pulmonary hypertension will expire in 2017 and our patents for Tyvaso will expire in the United States and in various countries throughout the EU in 2018 and 2020, respectively.

Upon the expiration of our patents, competitors may develop generic versions of our products and market those generic versions to compete with our products. Competitors may also seek to design around our patents prior to their expiration to develop competing products.

The scope of any patent may be insufficient to deter competitors and patent laws of international jurisdictions may not protect our rights to the same extent as the patent laws of the U.S. Furthermore, our suppliers' intellectual property protection may not be adequate. Consequently, competitors may attempt to invalidate our existing patents before they expire. In addition to patent protection,

we also rely on trade secrets, proprietary know-how and technological advances. We enter into confidentiality agreements with our employees and others, but these agreements may be ineffective in protecting our proprietary information.

To the extent third-party patents cover our products or services, we, or our strategic collaborators would be required to seek licenses from the holders of these patents in order to manufacture, use, or sell our products and services. Payments under these licenses would reduce our profits from the sale of related products and services. Moreover, we may be unable to obtain these licenses on acceptable terms or at all. If we fail to obtain a required license or are unable to alter the design of our technology to avoid infringing a third-party patent, we would be unable to market related products and services.

We may initiate litigation to enforce or defend our patents or proprietary rights; however, litigation can be time-consuming and costly and may not conclude favorably. If we are unsuccessful with respect to any future legal action in the defense of our patents and our patents are invalidated or canceled, our business could be negatively impacted. Furthermore, any licensed rights, patents or other intellectual property we possess may be challenged, invalidated, canceled, infringed or circumvented and therefore, may not provide us with any competitive advantage.

In July 2005, Vanderbilt University filed a lawsuit in the U.S. District Court for the District of Delaware against ICOS Corporation (ICOS) seeking to add three of its scientists as co-inventors of the tadalafil compound and method-of-use-patents. Lilly has since acquired ICOS. The patents that were the subject of this lawsuit are the same patents licensed to us by Lilly. In January 2009, the district court judge ruled in favor of ICOS/Lilly, declining to add any of these scientists as an inventor on either patent. The plaintiff has appealed this ruling. Lilly believes these claims are without legal merit and expects to prevail in the appeal; however, it is not possible to determine the outcome. An unfavorable final outcome could have a material adverse effect on our license for tadalafil.

We may not maintain adequate insurance coverage to protect us against significant product liability claims.

The testing, manufacturing, marketing, and sale of drugs and diagnostics involve product liability risks. Although we currently maintain product liability insurance, we may not be able to maintain this insurance at an acceptable cost, if at all. In addition, our insurance coverage may not be adequate for all potential claims. If claims or losses significantly exceed our liability insurance coverage, we may be forced out of business.

Our marketable investments maybe subject to a loss in value and liquidity.

There has been significant deterioration and instability in the financial markets. Even though we believe we take a conservative approach to investing our funds, these periods of extraordinary disruption and readjustment in the financial markets expose us to investment risk. Related risks could result in a significant loss of value and liquidity of our investments. Furthermore, issuers of the securities we hold could be subject to credit rating downgrades. This could result in future impairment charges with respect to our investment portfolio and our cash flows and operating results could be negatively affected.

If we need additional financing and cannot obtain it, our product development and sales efforts may be limited.

We may be required to seek additional sources of financing to meet unplanned expenditures. Unplanned expenditures could be significant and may result from necessary modifications to product development plans or product offerings in response to difficulties encountered with clinical trials. We may also face unexpected costs in preparing products for commercial sales, or in maintaining sales of Remodulin, Adcirca and Tyvaso. If we are unable to obtain additional funding on commercially reasonable terms or at all, we may be compelled to delay clinical studies, curtail operations or obtain funds through collaborative arrangements that may require us to relinquish rights to certain products or potential markets.

Furthermore, we may require additional financing to meet significant future obligations. Our Convertible Senior Notes require partial cash settlement. Specifically, upon conversion we will be required to pay in cash the principal balance of approximately \$250.0 million or the conversion value at the settlement date, whichever is less. The Convertible Senior Notes will mature in October 2011, but may be convertible prior to maturity at the election of their holders if certain criteria are met. In addition, awards granted under our Share Tracking Awards Plan (STAP) entitle participants to receive in cash an amount equal to the appreciation in our common stock, which is calculated as the positive difference between the closing price of our common stock on the date of exercise and the date of grant. Consequently, the STAP may require significant future cash payments to the extent the price of our common stock continues to appreciate and the number of vested STAP awards increases over time. If we do not have sufficient funds to meet our contractual obligations under the Convertible Senior Notes and the STAP or are unable to secure alternative sources of financing, we could be in default, face litigation and/or lose key employees.

Improper handling of hazardous materials used in our activities could expose us to significant liabilities.

Our research and development and manufacturing activities involve the controlled use of chemical and hazardous substances and we are expanding these activities both in their scale and in new locations. In addition, patients may dispose of treprostinil using means we do not control. Such activities subject us to numerous federal, state, and local environmental and safety laws and regulations that govern the management, storage and disposal of hazardous materials. Compliance with current or future environmental laws and regulations can require significant costs; furthermore, we can be subject to substantial fines and penalties in the event of noncompliance. While we believe we comply with laws and regulations governing these materials, the risk of accidental contamination or injury from these materials cannot be completely eliminated. Furthermore, once chemical and hazardous materials leave our site, we cannot control what our hazardous waste removal contractors choose to do with these materials. In the event of an accident, we could be liable for substantial civil damages or costs associated with the cleanup of the release of hazardous materials. Any related liability could exceed our resources and could have a materially adverse effect on our business, financial condition and results of operations.

We may encounter substantial difficulties managing our growth relative to product demand.

Several risks are inherent in our business development plans. Achieving our goals will require continued and substantial investment in research and development, sales and marketing, and facilities. For example, we have spent considerable resources building and seeking regulatory approvals for our laboratories and manufacturing facilities. These facilities may be insufficient to meet future demand for our products or we may have excess capacity at these facilities if future demand falls short of our expectations, or if we do not receive regulatory approvals for the products we intend to produce at these facilities. In addition, constructing our facilities is expensive, and our ability to recover our investment will depend on sales of the products manufactured at these facilities in sufficient volume to increase our revenues substantially. If we experience sales growth, we may have difficulty managing inventory levels as marketing new therapies is complicated, and gauging future demand is often difficult and uncertain.

Our ability to recognize the full value of our business tax credits may be limited.

As of June 30, 2009, we had approximately \$67.3 million in business tax credit carryforwards. These tax credit carryforwards expire on various dates through 2028. The Internal Revenue Service (IRS) has not yet audited or reviewed these business tax credits since we have not yet utilized them. We have conducted reviews of these business tax credits and have recognized reserves for those business tax credits that we believe may be disallowed upon examination by the IRS. However, it is possible that, upon examination, the IRS could reduce our business tax credits further. Any reduction in business tax credits will increase our tax expense and shorten the period before we are required to pay federal income taxes.

In addition, certain business tax credit carryforwards that were generated at various dates prior to December 2007 may be subject to limitations on their use pursuant to Internal Revenue Code Section 382 (Section 382) as a result of ownership changes as defined therein. Presently, we do not expect that these business tax credits will expire unused. If Section 382 ownership changes occur in the future, the utilization of related carryforwards may be deferred and may expire unused.

Furthermore, our future operations may not generate sufficient taxable income in order to utilize our business tax credit carryforwards. Consequently, all or a portion of our business tax credit carryforwards might expire unused.

We have been named as a party to a derivative lawsuit. Litigation proceedings are inherently uncertain and could result in an unfavorable outcome.

A derivative lawsuit has been filed against certain of our directors relating to the adoption of our STAP and the modification of awards granted under the STAP and repricing of certain stock options granted under our Amended and Restated Equity Incentive Plan. We have been named as nominal defendant in this lawsuit. A second complaint has been filed against us seeking access to records relating to these and other similar matters. See *Item 1 — Legal Proceedings* for a more detailed description of these proceedings. The defense of these lawsuits and any future actions could result in significant legal and accounting expenditures and the diversion of our management's time and attention from the operation of our business, and the outcome of the lawsuit may be costly and could have an adverse effect on the structure of our compensation plans and our ability to attract and retain employees. Furthermore, we may become the subject of additional private or governmental actions in the future relating to this litigation and/or other matters.

From time to time, we may be involved in other lawsuits and proceedings incidental to the conduct of our business. We are not a party to any other lawsuit or proceeding that, in the opinion of our management, is likely to have a material adverse effect on our financial position or results of operations.

Risks Related to Our Common Stock

The price of our common stock can be highly volatile and may decline.

The price of common stock can be highly volatile within the pharmaceutical and biotechnology sector. Consequently, there can be significant price and volume fluctuations in the market that may be unrelated to operating performance. The table below sets forth the high and low closing prices for our common stock for the periods indicated:

	High	Low
January 1, 2007—December 31, 2007	\$ 108.62	\$ 47.87
January 1, 2008—December 31, 2008	\$ 115.98	\$ 49.01
January 1, 2009—June 30, 2009	\$ 85.85	\$ 55.71

The price of our common stock could decline sharply due to the following factors, among others:

- Quarterly and annual financial and operating results;
- Failure to meet estimates or expectations of securities analysts;
- The results of our clinical trials;
- Physician, patient, investor or public concerns regarding the efficacy and/or safety of products marketed or being developed by us or by others;
- Changes in, or new legislation and regulations affecting reimbursement of Remodulin, Adcirca or Tyvaso by Medicare or Medicaid and changes in reimbursement policies of private health insurance companies;
- Announcements by us or others of technological innovations or new products or announcements regarding our existing products;
- Developments in patent or other proprietary rights;
- Substantial sales of our common stock by us or our existing stockholders;
- Future issuances of common stock by us or any other activity which could be viewed as being dilutive to our shareholders;
- Rumors among or incorrect statements by investors and/or analysts concerning our company, our products, or operations;
- Failure to maintain, or changes to, our approvals to sell Remodulin, Adcirca and Tyvaso;
- Discovery of previously unknown problems with our marketed products or problems with our manufacturing, regulatory, compliance, promotional or selling activities that result in regulatory restrictions on our products, including withdrawal of the products from the market;
- Failure to obtain or maintain regulatory approvals from the FDA and international regulatory agencies;
- Accumulation of significant short positions in our common stock by hedge funds or other investors or the significant accumulation of our common stock by hedge funds or other institutional investors with investment strategies that may lead to short-term holdings;
- Timing and outcome of additional regulatory submissions and approvals; and
- General market conditions.

We may fail to meet third-party projections for our revenue or profits.

Many independent securities analysts publish independently developed quarterly and annual projections of our revenues and profits. Such estimates are inherently subject to uncertainty. As a result, actual revenues and net income may differ from these projections, and even small variations in reported revenues and profits compared to securities analysts' expectations could have a significant impact on the price of our common stock.

Sales of our common stock may depress our stock price.

The price of our common stock could decline if: (i) we issue common stock to raise capital or to acquire a license or business; (ii) our stockholders transfer ownership of our common stock, or sell substantial amounts in the public market; or (iii) our investors become concerned that substantial sales of our common stock may occur. A decrease in the price of our common stock could make it difficult for us to raise capital or fund acquisitions through the use of our stock.

The conversion of some or all of the Convertible Senior Notes when the price of our common stock exceeds \$105.67 per share would dilute the ownership interests of our existing stockholders. Any sales of our common stock issued upon such conversion could adversely affect the prevailing market price of our common stock. Furthermore, the existence of the Convertible Senior Notes may encourage short selling by market participants because the conversion of the Convertible Senior Notes could depress the price of our common stock.

The fundamental change purchase feature of the Convertible Senior Notes may delay or prevent an otherwise beneficial attempt to take over our company.

We may be required to repurchase the Convertible Senior Notes by their holders in the event of a fundamental change, which includes a takeover of our company. This may delay or prevent a takeover of our company that would otherwise be beneficial to our stockholders.

Provisions of Delaware law and our certificate of incorporation, by-laws, shareholder rights plan, and employment and license agreements could prevent or delay a change of control or change in management that may be beneficial to our public stockholders.

Certain provisions of Delaware law and our certificate of incorporation, by-laws and shareholder rights plan may prevent, delay or discourage:

- a merger, tender offer or proxy contest;
- the assumption of control by a holder of a large block of our securities; and/or
- the replacement or removal of current management by our stockholders.

For example, our certificate of incorporation divides our board of directors into three classes. Members of each class are elected for staggered three-year terms. This provision may make it more difficult for stockholders to change the majority of directors. It may also deter the accumulation of large blocks of our common stock by limiting the voting power of such blocks.

Non-competition and other restrictive covenants in most of our employment agreements will terminate upon a change in control that is not approved by our Board.

We enter into certain license agreements that generally prohibit our counterparties to these agreements or their affiliates from taking necessary steps to acquire or merge with us, directly or indirectly throughout the term of these agreements, plus a specified period thereafter. We are also party to certain license agreements that restrict our ability to assign or transfer the rights licensed to us to third parties, including parties with whom we wish to merge, or those attempting to acquire us. These agreements often require that we obtain the prior consent of the counterparties to these agreements if we are contemplating a change in control. If our counterparties to these agreements withhold their consent, related agreements could be terminated and we would lose related license rights. These restrictive change-in-control provisions could impede or prevent mergers that could benefit our stockholders.

Our existing directors and executive officers own a substantial portion of our common stock and might be able to influence the outcome of matters requiring stockholder approval.

Our directors and executive officers beneficially owned approximately 6.5% of our outstanding common stock as of June 30, 2009. Shares beneficially owned include stock options that could be exercised by those directors and executive officers within 60 days of June 30, 2009. Accordingly, these stockholders as a group may be able to influence the outcome of matters requiring stockholder approval, including the election of our directors. Such stockholder influence could delay or prevent a change in control that could benefit our stockholders.

Because we do not intend to pay dividends, stockholders must rely on stock appreciation for any return on their investment in us.

We have never declared or paid cash dividends on any of our capital stock. Furthermore, we do not intend to pay dividends in the future. As a result, the return on an investment in our common stock will depend entirely upon the future appreciation in our stock price. There can be no assurances that our common stock will provide a return to investors.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

We held our 2009 annual meeting of shareholders on June 26, 2009, for the following purposes:

- (i) Election of the following three Class I directors nominated by our Board of Directors for terms expiring at the 2012 annual meeting of shareholders: Ray Kurzweil, Martine Rothblatt and Louis Sullivan; and
- (ii) Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation’s independent registered public accounting firm for 2009.

Results of the votes taken were as follows:

<u>Proposal</u>	<u>For</u>	<u>Withheld</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
(i) Election of Class I directors:					
Ray Kurzweil	11,216,429	11,912,216	—	—	—
Martine Rothblatt	11,730,164	11,398,481	—	—	—
Louis Sullivan	9,846,394	13,282,251	—	—	—
(ii) Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation’s independent registered public accounting firm for 2009					
	22,916,101	—	204,213	8,331	—

The terms of the following directors will continue beyond our 2009 annual meeting of shareholders: Christopher Causey, Raymond Dwek, Richard Giltner, R. Paul Gray, Roger Jeffs and Christopher Patusky.

Item 6. EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
3.1	Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant's Registration Statement on Form S-1 (Registration No. 333-76409)
3.2	Second Amended and Restated By-laws of the Registrant, incorporated by reference to Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2008
10.1	Amendment No. 2 to Construction Agreement between the Registrant and the Whiting-Turner Contracting Company, dated May 29, 2009
12.1	Ratio of Earnings to Fixed Charges
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Date: July 31, 2009

/s/ MARTINE A. ROTHBLATT

By: Martine A. Rothblatt, Ph.D.

Title: *Chairman and Chief Executive Officer*

/s/ JOHN M. FERRARI

By: John M. Ferrari

Title: *Chief Financial Officer and Treasurer*

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
3.1	Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant's Registration Statement on Form S-1 (Registration No. 333-76409)
3.2	Second Amended and Restated By-laws of the Registrant, incorporated by reference to Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2008
10.1	Amendment No. 2 to Construction Agreement between the Registrant and the Whiting-Turner Contracting Company, dated May 29, 2009
12.1	Ratio of Earnings to Fixed Charges
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**AMENDMENT NO. 2 TO STANDARD FORM OF AGREEMENT BETWEEN
OWNER AND CONSTRUCTION MANAGER**

This Amendment No. 2 (“Amendment”) to Standard form of Agreement between Owner and Construction Manager is entered into this 29th day of May, 2009 by and between United Therapeutics Corporation (“Owner”) and The Whiting-Turner Contracting Company (“Construction Manager”).

WHEREAS, Owner and Construction Manager entered into a Standard form of Agreement between Owner and Construction Manager dated as of February 15, 2007 (together with all exhibits, the “Contract”) pursuant to which the Construction Manager agreed to provide certain construction services relating to construction of a new Class A headquarters building for use as office space and fill-finish facilities and ancillary facilities located in Silver Spring, Maryland (the “Project”); and

WHEREAS, pursuant to Amendment No. 1 dated as of 11/21/08, the Owner and the Construction Manager agreed upon the Guaranteed Maximum Price and other terms and conditions associated therewith as contemplated by Section 2.2.3 of the Agreement portion of the Contract.

WHEREAS, Owner and Construction Manager desire to amend the Contract to modify certain terms therein, specifically, among other things, to convert the Guaranteed Maximum Price (as defined in the Contract) into a Lump Sum, confirm the date of Substantial Completion and modify the scope of Work.

NOW, THEREFORE, in consideration of the Recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. **Conversion of Guaranteed Maximum Price into Lump Sum**

The Guaranteed Maximum Price currently in effect under the Contract is hereby converted to the lump sum amount of Sixty Six Million Dollars (\$66,000,000.00) (the “Contract Sum”), of which \$33,361,617.00 has been previously invoiced by the Construction Manager thru 4/30/09 by the Owner (the “Contract Sum”). All references in the Contract to “Guaranteed Maximum Price” or “Contract Sum” shall hereinafter be deemed to refer to the lump sum amount stated above, as such amount may be adjusted in the future in accordance with the terms of the Contract Documents. The Schedule of Values reflecting the new Contract Sum is attached hereto as Exhibit A. Notwithstanding anything in the Contract to the contrary, the Construction Manager shall continue to be obligated to provide to the Owner and its accountants any and all cost segregation data required for tax purposes.

2. Substantial Completion Date

The date of Substantial Completion upon which the Contract Sum stated in Section 1 and the scope of Work stated in Section 3 are based is November 16, 2009; such date may be adjusted in the future in accordance with the terms of the Contract Documents. The Project Schedule reflecting this date of Substantial Completion is attached hereto as Exhibit B.

3. Scope of Work

The scope of Work on which the Contract Sum set forth in Section 1 and the date of Substantial Completion set forth in Section 2 are based is the scope of Work as set forth in Amendment No. 1, as modified by (a) the changes in scope listed on Exhibit C attached hereto and (b) the assumptions, qualifications and exclusions listed on Exhibit D. The parties acknowledge and agree that all time and compensation associated with the changes in scope listed on Exhibit C have already been reflected in the Contract Sum set forth in Section 1 and the date of Substantial Completion set forth in Section 2, and the Construction Manager hereby waives any additional compensation or extensions of time on account of the items listed in Exhibit C.

4. Modification of Certain Terms and Conditions of Agreement portion of Contract

Attached hereto as Exhibit E are certain provisions of the Agreement and General Conditions portions of the Contract that are modified as a result of this Amendment.

5. Full Force and Effect

Except as amended hereby, the Contract shall remain in full force and effect and unmodified.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized representatives on the day and year above written.

**OWNER:
UNITED THERAPEUTICS CORPORATION**

By: /s/ John Ferrari
Name: John M. Ferrari
Title: Chief Financial Officer

**CONSTRUCTION MANAGER:
THE WHITING-TURNER CONTRACTING COMPANY**

By: /s/ Timothy Regan
Name: Timothy J. Regan
Title: Senior Vice President

Exhibit E
Specific Changes to Contract

The following sections replace the corresponding sections in the Agreement and General Conditions:

Agreement

§ 4.1.1 For the services described in Sections 2.1 and 2.2, the Construction Manager's compensation shall be calculated as follows:

See Exhibit G. In the event the Contract is terminated prior to issuance of the Notice to Proceed, the compensation set forth in Exhibit G for Preconstruction Services shall be the total amount payable by the Owner to the Construction Manager on account of Preconstruction Services (excepting payment for construction services authorized in writing prior to issuance of the Notice to Proceed). In the event the Notice to Proceed is issued, all amounts paid for Preconstruction Services shall be deemed to be part of the Contract Sum.

§ 5.1 COMPENSATION

§ 5.1.1 The Owner shall pay the Contractor the Contract Sum in current funds for the Contractor's performance of the Contract. The Contract Sum shall be as set forth in Section 1 of Amendment No. 2, subject to additions and deductions as provided in the Contract Documents.

§ 5.2 Paragraphs deleted

§ 5.3 CHANGES IN THE WORK

§ 5.3.1 Adjustments to the Contract Sum on account of changes in the Work may be determined by the applicable methods listed in Section 7.3.3 of the General Conditions.

§ 5.3.2 Adjustments to subcontracts awarded with the Owner's prior written consent on the basis of cost plus a fee shall be calculated in accordance with the terms of those subcontracts. The Construction Manager hereby agrees that for changes in the Work performed by a subcontractor, (A) the payment to the subcontractor shall be equal to (i) the actual cost incurred in performing such changed work; (ii) a markup of 10% of such actual cost for overhead; and (iii) fee of 5% of actual cost. Notwithstanding the foregoing, the total amount payable to subcontractors of every tier on account of overhead and fee for a change to the Work shall not exceed 25%. In addition, the Construction Manager shall be entitled to Construction Manager's Fee equal to the percentage stated in Exhibit G, based on the total amount payable to the subcontractor; provided, however, that the Construction Manager shall not be entitled to Construction Manager's Fee on the first \$500,000 of Change Orders. There shall be no reduction in Construction Manager's Fee for deductive Change Orders. See Annex 2 to Exhibit G for examples of how markups and fees are calculated.

§ 5.3.3 Paragraphs deleted

ARTICLE 6 Paragraphs deleted

ARTICLE 7 CONSTRUCTION PHASE

§ 7.1 PROGRESS PAYMENTS

§ 7.1.1 Based upon Applications for Payment submitted to the Project Manager by the Construction Manager and approved by the Owner and the Project Manager, the Owner shall make progress payments on account of the Contract Sum to the Construction Manager as provided below and elsewhere in the Contract Documents.

§ 7.1.2 The period covered by each Application for Payment shall be one calendar month ending on the last day of the month.

On or before the 25th calendar day of each month (or in the event such day is a holiday or weekend day, the preceding business day) the Owner, the Project Manager and the Construction Manager (and the Architect and/or Fill/Finish A/E, if requested by the Owner) shall meet to review a preliminary draft of such Application for Payment (a "Pencil Draw"), prepared by the Construction Manager. Within three (3) days after the meeting described in the previous sentence, the Construction Manager shall (a) revise the Pencil Draw in accordance with any objection or recommendations of either Owner, or Project Manager that is consistent with the requirements for the Contract Documents, and (b) re-submit the revised Pencil Draw to the Owner and the Project Manager as the final Application for Payment. Such Pencil Draw and subsequent Application for Payment shall include a projection of the Cost of the Work through the then-current month.

§ 7.1.3 Provided an Application for Payment is received by the Owner and Project Manager not later than the last business day of a month, the Owner shall make payment to the Construction Manager not later than the last day of the following month. If an Application for Payment is received by the Owner and Project Manager after the application date fixed above, payment shall be made by the Owner not later than the next scheduled progress payment, as described in the previous sentence. The Construction Manager shall make payment to its subcontractors within seven (7) business days after receipt of payment from the Owner. If the Owner becomes aware that any subcontractor is not being paid as required, the Owner may elect to issue joint checks, payable to the Construction Manager and such subcontractor for future payments due such subcontractor. In the event the Owner elects to issue joint checks as described above, the Owner shall not be required to pay Construction Manager's Fee on account of the amount set forth in such joint check(s), and the Contract Sum shall be reduced by amount equal to one and one half percent (1.5%) of the aggregate amount of joint checks issued.

§ 7.1.4 With each Application for Payment, the Construction Manager shall submit (i) its Waiver and Release of Liens and Claims, in the forms set forth in Exhibit H hereto, covering all Work performed through the date of the current Application for Payment, and conditioned only on payment; and (ii) Waivers and Releases of Liens and Claims from each subcontractor and supplier in the forms set forth in Exhibit H, covering all Work performed through the date of the prior month's Application for Payment.

§ 7.1.5 Each Application for Payment shall be based upon the most recent schedule of values submitted by the Construction Manager in accordance with the Contract Documents and approved in writing by the Owner. The schedule of values shall allocate the entire Contract Sum among the various portions of the Work, except that the Construction Manager's Fee shall be shown as a separate line item. The schedule of values shall be prepared in such form and supported by such data to substantiate its accuracy as the Owner and Project Manager may require. This schedule, unless objected to by the Owner, shall be used as a basis for reviewing the Construction Manager's Applications for Payment.

§ 7.1.6 Applications for Payment shall show the percentage completion of each portion of the Work as of the end of the period covered by the Application for Payment.

§ 7.1.7 Subject to other provisions of the Contract Documents, the amount of each progress payment shall be computed as follows:

- .1** Take that portion of the Contract Sum properly allocable to completed Work as determined by multiplying the percentage completion of each portion of the Work by the share of the Contract Sum allocated to that portion of the Work in the schedule of values, less retainage of ten percent (10%). Pending final determination of cost to the Owner of changes in the Work, amounts not in dispute shall be included as provided in Section 7.3.7 of the General Conditions even though the Contract Sum has not yet been adjusted by Change Order;
 - .2** Add that portion of the Contract Sum properly allocable to materials and equipment delivered and suitably stored at the site for subsequent incorporation in the Work or, if
-

approved in advance by the Owner, suitably stored off the site at a location agreed upon in writing), less retainage of ten percent (10%);

- .3 Subtract the aggregate of previous payments made by the Owner; and
- .4 Subtract amounts, if any, for which the Architect has withheld or nullified a Certificate for Payment as provided in Section 9.5 of the General Conditions.

§ 7.1.8 When the Work is 50% complete, no further retainage shall be withheld. Notwithstanding the foregoing, if at any time the Owner reasonably believes that the Work is not progressing satisfactorily, the Owner retains the right to reinstate the above-mentioned retainage in whole or in part. Retainage withheld shall be paid as part of the Application for Payment immediately following Substantial Completion of the Work, less 200% of the value of punch list items and other items of incomplete work. The Owner and the Construction Manager shall agree upon a mutually acceptable procedure for review and approval of payments and retention for subcontracts in writing. If a subcontractor has completed its portion of the Work (including all punch list items and delivery of all items required under the Contract Documents to close-out its subcontract) pursuant to any given subcontract, the Construction Manager may request the Owner to disburse the retainage being held by the Owner in respect of such Subcontractor, after delivering to the Owner any necessary consent to such disbursement from any sureties in form reasonably satisfactory to the Owner. If the Owner is reasonably satisfied the Subcontractor's work has been completed in accordance with the Contract Documents and the Owner has received satisfactory final waivers of liens and claims with respect to the Subcontractor's work, the Owner shall disburse said retainage. Regardless of whether the Owner has disbursed said retainage to any Subcontractor, the warranty period referred to in the General Conditions or the other Contract Documents shall not begin with respect to the portion of the Work performed by such Subcontractor until the Date of Substantial Completion of the entire Work.

§ 7.1.9 Except with the Owner's prior written approval, the Construction Manager shall not make advance payments to suppliers for materials or equipment which have not been delivered and stored at the site, unless Owner is reasonably satisfied that the materials or equipment have been procured and are suitably and safely stored, insured and protected so as adequately to protect Owner's title thereto and/or interest therein.

§ 7.2 FINAL PAYMENT

§ 7.2.1 Final payment shall be made by the Owner to the Construction Manager when (1) the Contract has been fully performed by the Construction Manager except for the Construction Manager's responsibility to correct nonconforming Work, as provided in Section 12.2.2 of the General Conditions, and to satisfy other requirements, if any, which necessarily survive final payment; (2) a final Application for Payment has been submitted by the Construction Manager; (3) the Owner and the Project Manager have approved the final Application for Payment; and (4) final waivers and releases of liens and claims from the Construction Manager and all subcontractors and suppliers (contingent only upon final payment) have been received by the Owner; such final payment shall be made by the Owner not more than 30 days after the issuance of the Architect's final Certificate for Payment. If the aggregate of previous payments made by the Owner exceeds the amount due the Construction Manager, the Construction Manager shall reimburse the difference to the Owner.

§ 7.2.2 Paragraphs deleted

§ 7.2.3 Paragraphs deleted

§ 7.2.4 Paragraphs deleted

General Conditions

§ 1.1.9 Paragraphs deleted

§ 3.6 TAXES

§ 3.6.1 The Contractor shall pay sales, consumer, use and similar taxes for the Work provided by the Contractor. To the extent the Contractor is required to pay sales, consumer, use and similar taxes (other than taxes on the income of the Contractor or its Subcontractors) that were not legally enacted as of the date of the Agreement (whether or not yet effective or merely scheduled to go into effect), the Contractor shall be entitled to an increase in the Contract Sum equal to the amount of such additional taxes (without markup for overhead or profit). The Contractor acknowledges that certain tax exemptions are available to the Owner. The Contractor shall take such steps as are necessary for such tax exemptions to be available. If the Contractor fails to take such actions and taxes are due, such taxes shall be borne by the Contractor.

§ 9.2 SCHEDULE OF VALUES

§ 9.2.1 Before the first Application for Payment, the Contractor shall submit to the Owner and the Project Manager a schedule of values allocated to various portions of the Work, prepared in such form and supported by such data to substantiate its accuracy as the Owner may require. This schedule, unless objected to by the Owner or the Project Manager, shall be used only as a basis for reviewing the Contractor's Applications for Payment where appropriate under the Contract Documents. The Owner shall have the authority to adjust the schedule of values from time to time on the basis of modifications of subcontracts and allocations of estimates to actual costs. The schedule of values and each Application for Payment shall list separately all Change Orders issued by the Owner prior to the date of the particular Application for Payment (including as a single line item all of the costs of such Change Order). The schedule of values shall be prepared in such a manner that each item of Work and each subcontracted item of Work is shown as a single line item on AIA Documents G702/703, Application and Certificate for Payment, and Continuation Sheet.

§ 9.3.6 The Contractor warrants that title to all Work covered by an Application for Payment will pass to the Owner no later than the time of payment. The Contractor further warrants that upon submittal of an Application for Payment all Work for which payments have been received from the Owner shall, to the best of the Contractor's knowledge, information and belief, be free and clear of liens, claims, security interests or encumbrances in favor of the Contractor, Subcontractors, material suppliers, or other persons or entities making a claim by reason of having provided labor, materials and equipment relating to the Work.

.1 The Contractor further expressly undertakes to defend the Owner Indemnitees, at the Contractor's sole expense, against any actions, lawsuits or proceedings brought against the Owner Indemnitees as a result of liens filed against the Work, the Project site, the site of any of the Work, payments due the Contractor or any portion of the property of any of the Owner Indemnitees (referred to collectively as "Liens"). The Contractor hereby agrees to indemnify and hold the Owner Indemnitees harmless against any damages, costs, expenses (including, without limitation, reasonable attorneys' fees), losses, claims and liabilities arising out of or in connection with Liens or claims of Lien, unless such Lien is due solely to a failure by the Owner to pay the Contractor amounts properly due and owing. The Contractor hereby agrees that Liens filed on account of amounts which are subject to a good faith dispute between the Owner and the Contractor shall nevertheless be required to be bonded off by the Contractor, but in the event the Contractor prevails on account of such claim, the premiums associated with providing such bond shall be reimbursable pursuant to Change Order, without markup.

.2 The Contractor shall discharge all Liens within five (5) days after written notice by the Owner, and may contest a Lien only if the Contractor furnishes the Owner with security acceptable to the Owner or procures a lien release bond that complies with the requirements of the lien laws of the State of Maryland and those set forth below in this subsection .2. The Owner shall release any payments withheld due to a Lien or claim of Lien if the Contractor obtains security acceptable to the Owner or a lien release bond which is: (i) issued by a surety acceptable to the Owner, ii) in form and substance satisfactory to the Owner and (iii) in an amount not less than one hundred twenty five percent (125%) of such Lien. By posting a lien release bond or other acceptable security, however, the Contractor shall not be relieved of any responsibilities or obligations under this Section 9.3, including, without limitation, the duty to defend and indemnify the Owner Indemnitees.

.3 Notwithstanding anything to the contrary in the Contract Document, if the Contractor fails to post a bond or other security acceptable to the Owner in connection with any Lien or claim of Lien, the Owner may discharge such Lien or Lien claim by payments to the lien claimant or by such other means as the Owner, in the Owner's sole discretion, determines is the most economical or advantageous method of settling the dispute. The Contractor shall promptly reimburse the Owner, upon demand, for any payments so made. In such case, the Contractor shall have no claim against the Owner relating to the appropriateness or propriety of payment so made

United Therapeutics Corporation
Ratio of Earnings to Fixed Charges
(Unaudited)

	Six Months Ended June 30,	Year Ended December 31,				
	2009	2008	2007	2006	2005	2004
\$ in thousands, as adjusted(1)						
Earnings:						
Earnings (losses) from continuing operations before income taxes	\$ 14,454	\$ (83,721)	\$ 4,477	\$ 37,973	\$ 47,522	\$ 15,449
Add:						
Loss from equity investee	57	226	321	491	754	785
Fixed charges	9,040	17,357	16,855	3,589	29	3
Less: Capitalized interest	(2,992)	(4,757)	(689)	—	—	—
Earnings, as adjusted	<u>\$ 20,559</u>	<u>\$ (70,895)</u>	<u>\$ 20,964</u>	<u>\$ 42,053</u>	<u>\$ 48,305</u>	<u>\$ 16,237</u>
Fixed charges:						
Interest expense(2)	\$ 5,885	\$ 11,439	\$ 14,281	\$ 2,417	\$ 29	\$ 3
Capitalized interest	2,992	4,757	689	—	—	—
Portion of rentals representative of interest factor	163	1,161	1,885	1,172	—	—
Fixed charges	<u>\$ 9,040</u>	<u>\$ 17,357</u>	<u>\$ 16,855</u>	<u>\$ 3,589</u>	<u>\$ 29</u>	<u>\$ 3</u>
Ratio of earnings to fixed charges	<u>2.27</u>	<u>(4.08)</u>	<u>1.24</u>	<u>11.72</u>	<u>1,665.69</u>	<u>5,412.33</u>
Excess of fixed charges over earnings	<u>\$ —</u>	<u>\$ 88,252</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

- (1) Years ended December 31, 2006 through 2008 have been adjusted for the retrospective adoption of FSP APB 14-1. See Note 9: *Debt — Adoption of FSP APB 14-1* to the Consolidated Financial Statements included in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2009 .
- (2) Includes amortization of debt discount and issue costs.

NOTE: The Ratio of Earnings to Fixed Charges should be read in conjunction with the Consolidated Financial Statements and related Notes to the Consolidated Financial Statements and Management's Discussion and Analysis of Financial Condition and Results of Operations contained within our Annual Report on Form 10-K for the year ended December 31, 2008, and the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2009.

**CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934**

I, Martine A. Rothblatt, certify that:

1. I have reviewed this quarterly report on Form 10-Q of United Therapeutics Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2009

/s/ MARTINE A. ROTHBLATT

By: Martine A. Rothblatt, Ph.D.

Title: *Chairman and Chief Executive Officer*

**CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934**

I, John M. Ferrari, certify that:

1. I have reviewed this quarterly report on Form 10-Q of United Therapeutics Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2009

/s/ JOHN M. FERRARI

By: John M. Ferrari

Title: *Chief Financial Officer and Treasurer*

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of United Therapeutics Corporation (the "Company") on Form 10-Q for the period ended June 30, 2009, as filed with the Securities and Exchange Commission (the "Report"), I, Martine A. Rothblatt, Chief Executive Officer of the Company, certify, to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

July 31, 2009

/s/ MARTINE A. ROTHBLATT

Martine A. Rothblatt, Ph.D.

Chairman and Chief Executive Officer

United Therapeutics Corporation

THE FOREGOING CERTIFICATION IS BEING FURNISHED SOLELY PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 AND IS NOT BEING FILED AS PART OF THE FORM 10-Q OR AS A SEPARATE DISCLOSURE DOCUMENT.

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, OR OTHER DOCUMENT AUTHENTICATING, ACKNOWLEDGING, OR OTHERWISE ADOPTING THE SIGNATURE THAT APPEARS IN TYPED FORM WITHIN THE ELECTRONIC VERSION OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, HAS BEEN PROVIDED TO UNITED THERAPEUTICS CORPORATION AND WILL BE RETAINED BY UNITED THERAPEUTICS CORPORATION AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of United Therapeutics Corporation (the "Company") on Form 10-Q for the period ended June 30, 2009, as filed with the Securities and Exchange Commission (the "Report"), I, John M. Ferrari, Chief Financial Officer of the Company, certify, to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

July 31, 2009

/s/ JOHN M. FERRARI

John M. Ferrari
Chief Financial Officer and Treasurer
United Therapeutics Corporation

THE FOREGOING CERTIFICATION IS BEING FURNISHED SOLELY PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 AND IS NOT BEING FILED AS PART OF THE FORM 10-Q OR AS A SEPARATE DISCLOSURE DOCUMENT.

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, OR OTHER DOCUMENT AUTHENTICATING, ACKNOWLEDGING, OR OTHERWISE ADOPTING THE SIGNATURE THAT APPEARS IN TYPED FORM WITHIN THE ELECTRONIC VERSION OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, HAS BEEN PROVIDED TO UNITED THERAPEUTICS CORPORATION AND WILL BE RETAINED BY UNITED THERAPEUTICS CORPORATION AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.